REVIEW article

Front. Synaptic Neurosci., 10 October 2025

Volume 17 - 2025 | https://doi.org/10.3389/fnsyn.2025.1661342

AMPA receptors in the evolving synapse: structure, function, and disease implications

  • Centre for Neuroscience, Indian Institute of Science, Bengaluru, India

Abstract

Synapses, once considered static conduits for neuronal signals, are now recognized as dynamic, multifunctional structures critical to brain function, plasticity, and disease. This evolving understanding has highlighted the tripartite nature of synapses, including pre-synaptic terminals, post-synaptic compartments, and regulatory glial elements. Among excitatory synapses, glutamatergic transmission dominates, with AMPA receptors (AMPARs) playing a central role in fast synaptic signaling. AMPARs are tetrameric, ligand-gated ion channels that mediate rapid depolarization and are tightly regulated by subunit composition, trafficking, and interactions with scaffolding and signaling proteins. Their activity-dependent modulation underpins key processes such as long-term potentiation and depression, central to learning and memory. Importantly, dysfunctions in AMPAR expression, localization, or signaling are increasingly linked to neurological and psychiatric disorders including autism spectrum disorders, epilepsy, schizophrenia, and Alzheimer's disease. This review discusses AMPAR biology in the context of synaptic organization, highlighting recent advances and ongoing challenges in understanding their roles in health and disease.

Introduction

Over the past three decades, our understanding of synapses, the fundamental units of communication between neurons, has evolved dramatically. Once regarded as static junctions responsible solely for transmitting signals across neurons, synapses are now recognized as dynamic, multifunctional structures, finely tuned in space and time. Advances in molecular and imaging technologies have revealed that synaptic composition and organization are not fixed but instead undergo rapid and localized changes with nanometer-scale spatial precision and submillisecond temporal resolution (Nair et al., 2013; ; ). This transformation in perspective has led to the recognition that synapses are not merely neuronal interfaces; they are also the fundamental building blocks of neuronal communication. They are now understood as tripartite functional units composed of the pre-synaptic terminal, the post-synaptic membrane, and a third regulatory element, often glial cells, particularly astrocytes (; Szatkowski et al., 1990; ; ; Villegas, 1972). These non-neuronal cells are not passive bystanders; rather, they actively modulate synaptic strength and contribute to the homeostatic regulation of both the immediate synaptic environment and broader neuronal networks (Perea et al., 2009; ). This insight has expanded our conceptual framework of how information is processed and stored in the brain and has opened new avenues for exploring mechanisms of synaptic dysfunction in disease.

A significant portion of this new understanding has come from studies of excitatory synapses in the mammalian brain. Among the various neurotransmitter systems that mediate excitation, glutamatergic synapses predominate, accounting for approximately 80–90% of excitatory synaptic activity (Somogyi et al., 1998; Shinohara and Hirase, 2009). These synapses are predominantly localized to the dendritic spines, with small, actin-rich protrusions emerging from the dendritic shaft (Weber et al., 2016; Segal, 2005). Each spine typically receives input from a single pre-synaptic bouton, which contains synaptic vesicles filled with glutamate. Upon stimulation, glutamate is released into the synaptic cleft, where it binds to receptors on the post-synaptic membrane. This event triggers the depolarization of the spine and initiates the post-synaptic signaling cascade that determines the likelihood of generating an action potential (Qu et al., 2009; ). The structural and functional compartmentalization provided by dendritic spines enables localized signal processing, allowing neurons to integrate thousands of synaptic inputs with remarkable specificity and plasticity (Tecuatl et al., 2021; ). Over the last two decades, detailed molecular dissection of synaptic architecture has revealed a complex network of proteins involved in synaptic transmission, plasticity, and stability. Key among these are the molecular sensors and receptors that detect the arrival of neurotransmitters in the synaptic cleft. These include ionotropic receptors such as AMPA and NMDARs, which mediate fast excitatory transmission, as well as metabotropic glutamate receptors that modulate slower, longer-lasting synaptic responses (Watkins and Evans, 1981; ; ). The trafficking, localization, and functional tuning of these receptors are tightly regulated by scaffolding proteins, kinases, and other signaling molecules that collectively form the post-synaptic density (PSD)—a dense, protein-rich structure critical to synaptic integrity. The pre-synaptic machinery is equally intricate, involving vesicle docking, priming, and calcium-dependent fusion processes mediated by proteins such as synaptotagmins, SNAREs, and complexins (Sheng and Kim, 2011; Schoch and Gundelfinger, 2006; Scannevin and Huganir, 2000; ; MacGillavry et al., 2013; ). The coordinated activity of these proteins ensures that neurotransmitter release is both rapid and precisely timed. Importantly, many of these molecules are subject to activity-dependent regulation, providing a mechanistic basis for synaptic plasticity phenomena such as long-term potentiation (LTP) and long-term depression (LTD), which underlie learning and memory (Szatkowski et al., 1990; ; ).

Glutamate binds with Glutamate receptors and functions as an excitatory neurotransmitter in the Central Nervous System. Classically, Glutamate receptors are classified into two major types: ionotropic glutamate receptors (iGluRs) and metabotropic glutamate receptors (mGluRs). iGluRs, including α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartate (NMDA), and kainate receptors, are ligand-gated ion channels that directly affect neuronal excitability (Traynelis et al., 2010). On the other hand, mGluRs are G protein-coupled receptors that indirectly regulate neuronal activity through intracellular signaling pathways (Niswender and Conn, 2010). While early studies in synaptic biology emphasized how these molecular components ensure reliable neuronal signal transmission, contemporary research increasingly highlights their roles in neurological and psychiatric disorders. Our review focuses more on the roles of glutamate receptors, particularly AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, which are key mediators of fast excitatory synaptic transmission in the central nervous system. Discovered as ligand-gated ion channels responsive to the neurotransmitter glutamate, AMPARs are tetrameric complexes typically composed of GluA1-4, with distinct functional properties governed by their subunit composition, post-translational modifications, and interactions with auxiliary proteins (Miguez-Cabello et al., 2025; ; ). Functionally, AMPARs are critical for synaptic plasticity mechanisms such as LTP and LTD, which underlie learning and memory (; ). Their rapid trafficking to and from the synaptic membrane enables dynamic regulation of synaptic strength in response to activity patterns, positioning them as central molecular integrators of experience-dependent neural adaptation. Importantly, dysfunctions in AMPAR expression, localization, or signaling have been implicated in a wide range of brain disorders. Mutations in AMPAR subunits or their associated scaffolding proteins have been linked to autism spectrum disorders, intellectual disability, epilepsy, and schizophrenia (Yonezawa et al., 2022; ; ). Moreover, in neurodegenerative diseases like Alzheimer's, altered AMPAR trafficking and synaptic localization contribute to early synaptic failure and cognitive decline, often preceding neuronal loss (Zhang et al., 2022; ). As research continues to uncover the complex modulation of AMPARs across developmental, physiological, and pathological states, they remain a focal point in efforts to elucidate and correct the molecular basis of cognitive and behavioral dysfunctions. In this review, we will track a brief recap of the AMPA subtype of glutamatergic receptors, their implication in health and diseases, and current challenges and advances that allow us to dissect the roles of these molecules from the perspectives of synapses and synaptic organization.

Glutamate in the brain and its function

L-glu is the major excitatory neurotransmitter involved in functions such as learning and memory, long-term potentiation, and synaptic plasticity (Zhou and Danbolt, 2014; Tapiero et al., 2002; Petroff, 2002; McKenna, 2007; ; ). A kilogram of brain tissue contains 5–15 mmol L-glu, depending on the region, which far exceeds concentrations of all other amino acids (Schousboe, 1981). Neurons also show very high activity when it comes to L-glu uptake (Stern et al., 1949). L-glu's excitatory effect was later discovered as well (; , ). L-glu release from pre-synaptic vesicles occurs via Ca2+-dependent exocytosis triggered by voltage-gated calcium channels (Meldrum, 2000; ). With vesicular L-glu concentrations reaching ~100 mM, the release of a single vesicle generates an excitatory post-synaptic potential (EPSP) (Meldrum, 2000). Virtually all nervous system cells express at least one glutamate receptor subtype (Vernadakis, 1996; Shelton and McCarthy, 1999; ). Studies involving Glutamate receptor-mediated mechanisms have not only led to the development of treatments for Glutamate-related neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and multiple sclerosis, but also a basic understanding of synapses and how the brain controls structure-function relationship from molecular, and cellular levels that have repercussions in cognitive processes (Pizzi et al., 2005).

Glutamate receptors

Glutamate receptors comprise two structurally distinct families of transmembrane proteins: iGluR and mGluRs (Watkins and Evans, 1981; ). IGluR facilitate rapid synaptic signaling. Structurally, iGluRs function as tetrameric ligand-gated ion channels with distinct pharmacological profiles and electrophysiological characteristics (Traynelis et al., 2010). Excessive or prolonged activation of iGluRs and other post-synaptic signaling components can induce excitotoxicity, a process strongly linked to neurodegenerative diseases and nervous system injuries (; ; ). mGluRs, in contrast, are G-protein-coupled receptors (GPCRs) that activate downstream signaling cascades or modulate cation influx upon L-glu binding, regulating synaptic efficacy and plasticity (; Tikhonov and Magazanik, 2009). These receptors are widely distributed in the central and peripheral nervous systems and have been implicated in maintaining homeostasis across multiple organ systems (Niswender and Conn, 2010; ).

Extensive pharmacological research conducted between 1980 and 2000 established the canonical classification system for iGluRs, dividing them into three distinct functional categories: (1) AMPA-sensitive receptors, activated by α-amino-3-hydroxy-5-methyl-isoxazole-propionic acid (GluA1-GluA4), (2) kainate-sensitive receptors, activated by kainic acid (GluK1-GluK5), (3) NMDA-sensitive receptors, activated by N-methyl-D-aspartate (GluN1, GluN2A-D, GluN3A-B), and the orphan glutamate receptors (4) (GluD1 and GluD2) that formed a separate phylogenetic cluster classified as Delta receptors due to their unique sequence features and lack of known agonists, bringing the total to four major groups (Watkins and Evans, 1981; Yamazaki et al., 1992; Watkins et al., 1990; Stevens, 1986; Simon et al., 1976; Nowak et al., 1984; Lomeli et al., 1993; ; ) (Figure 1).

Figure 1

; Traynelis et al., 2010; Lomeli et al., 1993), along with the downstream signaling of mGluRs upon binding of mGluRs (; ). “*” indicates special conditions for the conduction of these ions.

As mentioned above, excitatory post-synaptic currents were initially categorized according to their kinetic and pharmacological properties, distinguishing between currents mediated by AMPA-, kainate-, and NMDA-type glutamate receptors (Watkins and Evans, 1981). However, there was a major drawback to this method of classifying glutamate receptors. There are subunits classified under glutamate receptors that do not bind glutamate. Subunits GluN3A and GluN3B of the NMDA family do not bind L-glu, and NMDA receptors consisting of them are insensitive to glutamate and instead bind glycine to form excitatory glycinergic receptors (Yao et al., 2008; Ulbrich and Isacoff, 2008; ; ). Also, five of the 18 vertebrate iGluR subunits, GluN1, GluN3A, GluN3B, GluD1, and GluD2, also bind glycine other than glutamate, while also endogenously interacting with the D-serine in multiple brain regions (Naur et al., 2007; ; ; ). Hence, now the classification has shifted to a more sequence homology-based approach.

The classes have different electrophysiological characteristics as well. AMPARs display rapid desensitization kinetics, while kainate receptors undergo more prolonged desensitization (Mosbacher et al., 1994; ; ). NMDARs possess unique activation requirements, demanding concurrent conditions: (1) glycine/serine binding, (2) pre-synaptic L-glu release, and (3) post-synaptic membrane depolarisation, removing a magnesium block from the channel pore, allowing the exchange of ions. This triple-gating mechanism establishes NMDARs as molecular coincidence detectors, particularly crucial for initiating molecular reorganization important for persistent long-term changes like LTP. They also (Tang et al., 1999; ; ). Recombinant delta receptors don't directly open on binding of agonists but have been shown to conduct depolarising current when induced by mGluRs (Wo and Oswald, 1995).

Ionotropic glutamate receptors: structure, function, and assembly

The molecular architecture of iGluR subunits consists of four distinct structural domains: (1) an extracellular N-terminal/amino-terminal domain (NTD/ATD), (2) an extracellular ligand-binding/agonist-binding domain (LBD/ABD), (3) a transmembrane domain (TMD), and (4) an intracellular carboxyl-terminal domain (CTD) (Sobolevsky et al., 2009; ) (Figure 2). The LBD forms through the interaction of two discontinuous polypeptide segments (S1 and S2) that flank the membrane-spanning regions. The TMD contains three transmembrane helices (M1, M3, M4) and a membrane-reentering loop (M2), while the CTD mediates subcellular targeting and regulatory post-translational modifications (Warnet et al., 2021; ; ). Ligand binding induces a conformational change in the LBD that mechanically couples to the TMD, causing structural rearrangements that open the ion conduction pathway. This gating mechanism, along with the presence of key amino acids that make up the selectivity filter of the channel pore, permits selective permeation of Na+, K+, and Ca2+ ions across the membrane (Twomey and Sobolevsky, 2018).

Figure 2

iGluRs function as tetrameric assemblies (Sobolevsky et al., 2009; ; Rosenmund et al., 1998; Nakagawa et al., 2005; Mano and Teichberg, 1998) with strict subunit selectivity, ensuring receptors form exclusively from members of the same pharmacological class (Monyer et al., 1992; Leuschner and Hoch, 1999; ; ; ). This assembly principle maintains the functional specificity of AMPA, kainate, NMDA, and Delta receptor subtypes.AMPARs have flexible assembly properties, with GluA1-GluA4 subunits capable of forming both homomeric as well as heteromeric complexes (; ; ). AMPARs comprise both calcium-impermeable (CI-AMPARs) and calcium-permeable (CP-AMPARs) subtypes, with CP-AMPARs distinguished by their lack of GluA2 subunits. GluA2-lacking AMPARs are permeable to calcium, whereas those containing GluA2 subunits are calcium-impermeable (). But recently it has been shown that GluA2-containing AMPARs are also permeable to calcium (Miguez-Cabello et al., 2025). CP-AMPARs exhibit unique biophysical and pharmacological signatures, enabling their functional identification. Studies have demonstrated their critical involvement in multiple forms of synaptic plasticity, like LTP (Park et al., 2019), LTD (Sanderson et al., 2016), and homeostatic plasticity (Sutton et al., 2006; Sanderson et al., 2018). In contrast, NMDARs exhibit strict subunit requirements: functional channels necessitate two obligatory GluN1 subunits combined with either two GluN2 subunits or a combination of GluN2 and GluN3 subunits (Ulbrich and Isacoff, 2008, 2007; Schorge and Colquhoun, 2003). Kainate receptors display intermediate assembly characteristics: GluK1-GluK3 subunits can form homomers or heteromers among themselves, while GluK4 and GluK5 require co-assembly with at least one GluK1-3 subunit for functionality (Reiner et al., 2012; Meyerson et al., 2016; ; ; ). The orphan Delta receptors GluD1 and GluD2 subunits assemble into homotetrameric complexes that function as trans-synaptic adhesion molecules and ion channels (Naur et al., 2007; Mayat et al., 1995; ).

Metabotropic glutamate receptors

Eight members of the G-protein-coupled mGluR family have been identified to date, namely mGluR1–8. Based on pharmacological properties, second messenger coupling, and sequence homology, mGluRs are classified into three groups: Group I (mGluR1 and mGluR5), Group II (mGluR2 and mGluR3), and Group III (mGluR4, mGluR6, mGluR7, and mGluR8) (Yin et al., 2014; ) (Figure 1). Group I mGluRs primarily signal through Gq/G11 proteins, activating phospholipase Cβ, whereas Group II and Group III mGluRs couple to Gi/Go proteins (; ; ; Valenti et al., 2002; ).

Group I mGluRs typically couple to Gq/G11 to activate phospholipase Cβ, triggering phosphoinositide hydrolysis that results in the formation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). This canonical pathway causes the release of intracellular calcium from the ER and activates protein kinase C (PKC). An increase in intracellular calcium also induces inhibitory post-synaptic potentials (IPSPs) via Ca2+-activated K? conductance (). However, these receptors are now known to regulate additional signaling cascades beyond Gq, including pathways mediated by Gi/o, Gs, and G protein-independent mechanisms (). Their downstream effects vary by cell type, modulating effectors like phospholipase D, multiple protein kinases like casein kinase 1, cyclin-dependent kinase 5, Jun kinase, and key pathways related to plasticity, particularly the MAPK/ERK and MTOR/p70 S6 kinase cascades (Page et al., 2006; Li et al., 2007; ). Group II and III mGluRs instead primarily signal through Gi/o proteins, which typically inhibit adenylyl cyclase while directly modulating ion channels and other effectors via the release of the G protein subunits Gβγ. Recently, emerging evidence has shown that these receptors also engage in other signaling pathways, including MAPK and PI3 kinase activation (). Even though mGluRs are capable of facilitating synaptic communication by generating prolonged excitatory post-synaptic depolarisations, their principal function lies in fine-tuning neural activity, where they adjust cellular responsiveness, information transfer across synapses, and adaptive changes in synaptic strength.

Structurally, mGluRs are dimeric and possess an extensive extracellular N-terminal region known as the Venus flytrap domain (VFD). This structural element harbors the L-glu binding pocket and plays an essential role in both homomer and heterodimer formation among these receptors (Pin et al., 2003; Muto et al., 2007; ; ) (Figure 3). Ligand binding induces conformational changes that propagate from the Venus flytrap domain (VFD) through cysteine-rich domains (CRDs) to the seven-transmembrane domain and the C-terminal tail (Muto et al., 2007; Rondard et al., 2006). The C-terminal domains of mGluRs play crucial roles in regulating G protein coupling. These regions also undergo alternative splicing, phosphorylation-dependent regulation, and modulatory protein-protein interactions in several mGluR subtypes (Niswender and Conn, 2010). MGluRs exhibit broad expression across the central nervous system, present in numerous major brain areas. They show precise localization patterns, occupying both synaptic and extrasynaptic compartments within neuronal and glial cells. They have also been associated with multiple neuropsychiatric disorders, including Fragile X syndrome, schizophrenia, and autism spectrum disorder ().

Figure 3

Evolution of glutamate as a major excitatory neurotransmitter

The seminal work of Curtis, Phillis, and Watkins demonstrated L-glu's capacity to induce depolarization in central neurons, establishing its potential as the primary excitatory neurotransmitter in the CNS (Moroz and Romanova, 2021). Evolutionarily, L-glu, ATP, and nitric oxide (NO) acquired neurotransmitter functions early in cellular evolution, with these signaling roles emerging concurrently in primitive cells (Moroz, 2009; ). Substantial evidence indicates that L-glu synthesis occurred on primordial Earth (>3.5–4 billion years ago) under reducing atmospheric conditions, driven by diverse energy inputs. L-glu represents the predominant metabolic intermediate across bacterial and mammalian systems, achieving intracellular levels of 96 mM in E. coli (Park et al., 2016), 44 mM in yeast, and 64 mM in immortalized baby mouse kidney (iBMK) epithelial cells (Ohwada and Sagisaka, 1987). Its pool size exceeds 20–40% of the total cellular metabolite content. Within bacterial biofilms, metabolic and electrical signaling networks emerge, with L-glu serving as a critical mediator between central and peripheral cell populations (Moran et al., 2015; Liu et al., 2015). L-glu functions as a versatile nutrient source, supplying carbon, nitrogen, and energy, and consequently, nearly all prokaryotic organisms require L-glu detection to maintain ecological competitiveness across diverse environments.

Structural evolution of iGluRs

Potassium channels likely served as the evolutionary precursors for glutamate receptors, representing a crucial exaptation event. Phylogenetic analyses indicate that potassium channels predate most other ion channel families, evidenced by the remarkable conservation of their transmembrane domains (Yu et al., 2005; Miller, 2000; ). The co-dependence of potassium and L-glu metabolism supports the proposed dual-origin model for iGluRs suggesting their emergence from (i) ancestral potassium channels and (ii) a nutrient-sensing ligand-binding domain (Tikhonov and Magazanik, 2009; ; ; ). It has been proposed that this complex architecture emerged from the fusion of multiple prokaryotic genes, each adding new domains. The domain organization of iGluRs is conserved across eukaryotes (; Scheepers et al., 2016), arising from the fusion of prokaryotic genes (e.g., KcsA + LAOBP). This modular evolution enabled specialization for L-glu signaling, while retaining ancestral roles in nutrient sensing () (Figure 4).

Figure 4

Eukaryotic iGluRs share an evolutionary lineage with bacterial GluR0-type potassium channels (; Schonrock et al., 2019; ). This homology extends to viral K-channel homologs, suggesting lateral gene transfer played a role in iGluR evolution. Prokaryotic iGluR-like structures are found in bacteria, cyanobacteria, and archaea, though these lack the NTD, M4 segment, and CTD present in eukaryotic iGluRs (Tikhonov and Magazanik, 2009; ; ). The transmembrane domain (TMD) of iGluRs, particularly M1, M2, and M3, shows high structural similarity to the bacterial potassium channel KcsA (K channel of Streptomyces A) (Schrempf et al., 1995; Meuser et al., 1999; ). This supports the hypothesis that GluR0 evolved from the insertion of KcsA between the two lobes of a periplasmic binding protein (LAOBP) (; ). Notably, GluR0 remains K-selective, while eukaryotic iGluRs are non-selective cation channels (; ). The bilobed LBD (S1/S2) of the Ligand-Binding Domain (LBD) originated from prokaryotic periplasmic substrate-binding proteins (SBPs), particularly the lysine-arginine-ornithine (LAOBP) and leucine-isoleucine-valine (LIVBP) binding families (; ).

The N-terminal domain (NTD) facilitates receptor tetramerization in the ER (Sia et al., 2007) and helps with interactions with N-cadherins, pentraxins, and ephrins (Saglietti et al., 2007; Paoletti et al., 2000). It also provides binding sites for regulatory ions/small molecules (Masuko et al., 1999; ). The Transmembrane Segment M4 provides cytoplasmic-facing C-termini, critical for post-translational modifications () and scaffolding protein interactions (Salussolia et al., 2011; ). It also helps with tetramer stabilization via conserved residues interacting with M1/M3 (Yuan et al., 2005). The M3 domain contains a highly conserved gating motif, maintaining a closed state in eukaryotes (; ), unlike bacterial GluR0s, which are passively open.

Major base substitutions also exist between humans and chimpanzees, including GluN3A-D71G (loss of myristoylation) and GluN3B-R727H (gain of phosphorylation), both directly affecting synaptic plasticity, LTP, and LTD ().

Role in synaptic transmission

Synaptic plasticity is defined by the experience-driven alteration of synaptic transmission efficacy at synapses, which is a fundamental mechanism of neural circuit adaptation and information processing. Synaptic plasticity is of two main types: short-term synaptic plasticity (STP), which lasts for tens to hundreds of milliseconds to several minutes and results in a temporal modification of synaptic efficiency, and LTP, which can have a duration of from minutes to hours, days, or even months. LTD is another form of synaptic plasticity that works antagonistically to LTP, resulting in a progressive weakening of synapses (). The concept of neuronal circuits was first introduced over a century ago by Spanish Nobel laureate Santiago Ramón y Cajal in his book, “Histology of the nervous system of man and vertebrates.” Histology of the nervous system of man and vertebrates (Ramón y Cajal, 1995), Oxford University Press. He identified the axonal growth cone and experimentally disproved the reticular theory (which posited the nervous system as a continuous network), instead demonstrating that neurons were contiguous yet separated (). This work presented concrete evidence for the “neuron theory,” now widely regarded as the foundation of modern neuroscience.

This foundation was expanded in the late 1940s by Donald Hebb, who theorized that associative memories emerge through synaptic strengthening when pre-synaptic activity coincides with post-synaptic firing (). This mechanism of synaptic plasticity, which encodes memories by detecting coincident events, provides a compelling cellular explanation for behavioral learning paradigms like the classical Pavlovian conditioning (Pavlov, 2010). Growing evidence suggests that impaired synaptic plasticity may underlie many neuropsychiatric disorders (). These will be discussed in the latter parts of the review.

The majority of excitatory synapses in the mammalian brain are glutamatergic, where pre-synaptic activity triggers the fusion of glutamate-packed vesicles. The released L-glu diffuses across the ~20 nm synaptic cleft and binds to post-synaptic glutamate receptors (). AMPARs facilitate fast excitatory L-glu signaling in the mammalian CNS by gating rapid sodium channel activity. These receptors dynamically adjust to neuronal activity patterns through swift insertion into or removal from post-synaptic membranes. Synaptic strength strengthens during LTP through increased AMPAR incorporation, while LTD weakens connections via receptor removal ().

The discovery of silent synapses fuelled the search for the role of AMPARs in Early LTP. Silent synapses in the CA1 region of the hippocampus are characterized by the absence of detectable excitatory post-synaptic currents (EPSCs) at resting membrane potential, despite receiving pre-synaptic L-glu release. This phenomenon is primarily attributed to synapses containing NMDARs but lacking functional AMPARs under basal conditions. However, these synapses can be functionally “unsilenced” upon post-synaptic depolarisation and induction of NMDA, leading to insertion of AMPARs, which allows previously silent synapses to participate in neuronal communication (Makino and Malinow, 2009; Lledo et al., 1998; Liao et al., 1995; ). These silent synapses play a crucial role in synaptic plasticity and are particularly abundant during early development, decreasing in number with maturation (Lüscher et al., 1999).

AMPAR insertion occurs primarily in perisynaptic zones rather than directly at the synaptic site. From these regions, the receptors are incorporated into the membrane and subsequently diffuse laterally to reach synaptic locations (Penn et al., 2017). This mechanism allows for controlled delivery and integration of AMPARs into the post-synaptic density during synaptic plasticity. The GluA1 subunit is especially crucial for the activity-driven insertion of AMPARs during LTP. AMPARs exhibit high mobility, freely diffusing in and out of synapses until being anchored by PDZ domain-containing scaffolding proteins (primarily PSD-95) at the post-synaptic density. This is followed by synaptic entry via lateral diffusion ().

Late-LTP involves new protein synthesis, including AMPAR subunits and auxiliary proteins, to sustain this now-established synaptic strengthening. Dendritic spines enlarge, and new synapses form, increasing the number of AMPARs (Penzes et al., 2008; Okuno et al., 2012; Murakoshi et al., 2011). In LTD, AMPARs are internalized via endocytosis, weakening synapses (; ; ).

LTP and LTD represent Hebbian synaptic plasticity mechanisms that function at single synapses to store particular information. Alternatively, homeostatic plasticity describes neurons' capacity to maintain network stability by globally adjusting synaptic strength upward or downward to prevent either complete silence or excessive activity (Turrigiano et al., 1998; Turrigiano, 2012; Pozo and Goda, 2010). Like Hebbian synaptic plasticity, homeostatic scaling regulates synaptic strength by adjusting AMPAR surface expression. During scaling up, synaptic levels of GluA1-containing AMPARs rise, including both GluA1 homomers and GluA1/GluA2 heteromers (Soares et al., 2013; ; ). Prolonged neuronal activity suppression (via TTX) multiplicatively increases synaptic AMPAR levels, with GluA1 exhibiting greater upregulation (scaling factor: 1.30) than GluA2 (1.16), indicating subunit-specific regulation in homeostatic plasticity (Venkatesan et al., 2020). During homeostatic scaling down, AMPARs containing GluA1 subunits are selectively internalized from synapses (Widagdo et al., 2017).

Synapses are highly dynamic structures, and AMPARs exhibit continuous movement even in the absence of neuronal activity (Nair et al., 2013; ; ). These receptors undergo constitutive trafficking between endosomes and the cell surface, with a half-life of 1–2 days (Passafaro et al., 2001; Ojima et al., 2021; O'Brien et al., 1998). The surface delivery of AMPARs is subunit-specific (Tian et al., 2015; Shi et al., 2001) and regulated by accessory proteins, such as transmembrane AMPAR regulatory proteins (TARPs).

Moving forward, the review will be focused specifically on AMPARs due to their sheer abundance and importance in excitatory synaptic transmission.

AMPAR

AMPA Glutamate receptors are the primary excitatory neurotransmitter in the brain, mediating rapid signaling throughout the brain. AMPAR is composed of four subunits (GluA1-GluA4) and assembles to form tetrameric ion channels with two-fold symmetry. Each of these subunits contributes differently to receptor trafficking, selectivity, and kinetics (Miguez-Cabello et al., 2025). The pore-forming subunits (GluA1-GluA4) of AMPAR are made up of four distinct domains, the extracellular N-terminal domain (NTD) which functions for subunit assembly, synaptic localization, and receptor clustering (Rossmann et al., 2011; ), the Ligand Binding Domain (LBD) which functions to bind L-glu and channel gating followed by the Transmembrane Domain (TMD), which is composed of three helix (M1, M3, and M4) and one re-entrance helix-loop (M2), this TMDs function for ion conductance by the AMPAR (; ), and finally the fourth domain is a cytoplasmic C-terminal domain (CTD) which is involved in controlling receptor anchoring, intracellular signaling, and trafficking (; ). Based on the permeability of AMPAR for Calcium (Ca2+), they are functionally grouped into two types: Ca2+ permeable or Ca2+ impermeable AMPAR. The permeability of AMPAR for calcium is determined by the presence or absence of Q/R edited GluA2 subunit. GluA2-containing AMPARs that are Q/R site–edited predominantly in the central nervous system and are impermeable to Ca2+ (Miguez-Cabello et al., 2025; Seeburg and Hartner, 2003). Dysregulation of Q/R site editing in GluA2R has also been linked to the development of AD, both in human and mouse models (Wright et al., 2023; ). The number of AMPARs at any given synapse is subject to regulation by neuronal activity. The retention of AMPAR at the synaptic site involves three distinct steps: 1. exocytosis of the intracellular AMPARs, 2. Lateral diffusion of these receptors toward synaptic sites and 3. Anchoring at the synaptic site through interaction with scaffolding proteins (Opazo and Choquet, 2011).

Auxiliary subunits associated with AMPARs

Although the native AMPAR complex is composed of the assembly of four GluA subunits, the functional AMPAR has auxiliary subunits associated with it. Some of the well-studied auxiliary subunits include TARPs (Tomita et al., 2005; ), cornichons (CNIHs) (Schwenk et al., 2009), CKAMP44 (Shisa9) (von Engelhardt et al., 2010), Shisa6 (), SynDIG1/Prrt1, SynDIG4 (), and GSG1L (Perozzo et al., 2023) as shown in Figure 5. These auxiliary subunits are known to add functional diversity for channel gating kinetics and receptor localization.

Figure 5

TARPs

The two most abundant AMPAR auxiliary subunits in the hippocampus, cortex, and striatum are TARPs and CNIHs. Structurally, TARP proteins are claudin-like proteins that were identified as having protein homology to the γ-subunits of voltage-dependent calcium channels (VDCC), which are known to regulate the function of AMPARs in the post-synaptic membrane (Twomey et al., 2019a). Based on the sequence and function, TARPs are classified into three types: Type 1a (γ2, γ3), Type 1b (γ4, γ8), all of which are positive modulators of AMPAR, while Type 2 (γ5, γ7) exhibit distinct and diverse functions. In situ hybridization and western blotting experiments by Tomita et al. (2003) have shown that TARPs show a regional distribution in the brains, the highest level of TARP γ2 occurred in the cerebellum, γ-3 in the cerebral cortex, γ-4 in the olfactory bulb, and γ-8 in the hippocampus (Tomita et al., 2003). The primary point of interaction between AMPAR–TARP is TMD, where auxiliary subunits act as a scaffold around the AMPAR (Shaffer et al., 1987). TARPs subunits are known to regulate various properties of AMPAR, such as mean channel conductance, channel kinetics (Shaffer et al., 1987; Priel et al., 2005), polyamine sensitivity (Soto et al., 2007), opening probability (Priel et al., 2005), localization, and trafficking of AMPAR to PSD95 (). Experimental evidence from Opazo et al. (2010) has shown that phosphorylation of the C-terminal tail of Stargazin by CAMKII causes the diffusional trapping and accumulation of AMPARs at the synaptic site, enhancing the surface localization of AMPAR (Opazo et al., 2010). Mechanistically, they found that phosphorylation elongates the length of the C-terminal tail, facilitating binding even to the farthest-located AMPAR and PSD-95 contributing to the increased synaptic transmission (). Yamazaki et al. (2004) also found that the co-expression of GluA2 with stargazing enhanced the export of GluA2 from the Endoplasmic Reticulum (ER) and increased the surface expression of GluA receptors.

The assembly of AMPARs begins in the endoplasmic reticulum (ER), where GluA subunits first form homo or hetero dimers to form tetramers. Experimental evidence from has given compelling evidence that TARPs associate with AMPARs in the ER at this early stage (). AMPARs undergo various post-translational modifications assisted by TARPs and interact with additional trafficking-associated proteins such as nPIST (), MAP1 LC2 (), and AP-4 (Matsuda et al., 2008), which are believed to assist in directing the receptor complex to the cell surface via vesicular transport. Co-immunoprecipitation experiments by Tomita et al. (2003) showed that the AMPARs co-immunoprecipitated with stargazing, suggesting that Stargazin strongly interacts with AMPAR. The PDZ-binding domains of type I TARPs, type II lacks it, located toward COOH of the terminus, interact with PSD-95 and immobilizes TARPs to the post-synaptic membrane, causing AMPARs to accumulate at post-synaptic sites (), contributing to the synaptic plasticity () and formation of macromolecular condensate, liquid-phase separation (Zeng et al., 2019). The PDZ-binding domain of TARP has a consensus site which acts as a substrate for various kinases, and phosphorylation of this site is known to disrupt the interaction with PSD-95, preventing synaptic clustering of AMPARs (; ).

Stargazin was first discovered in 1990 in A/J inbred mice line at the Jackson Laboratory. Mice homozygous for the autosomal recessive mutant form of the Cacng2 gene in chromosome 15 displayed a distinct clinical behavior of frequently looking upward, so the researchers named the mutation “stargazer” (Noebels et al., 1990). The ectodomain of Stargazin is known to influence the gating of AMPAR, thus shaping the post-synaptic current. To quantify the glutamate-evoked current in the presence of Stargazin, Tomita et al. (2005) injected varying amounts of Stargazin and GluA1 in oocytes and measured glutamate-evoked currents. They found that GluA1, which shows no detectable current on its own, produces nearly maximal current when co-expressed with stargazin. Furthermore, they investigated whether stargazin influences both receptor trafficking and channel properties. To quantify the surface expression of GluA1, they tagged the hemagglutinin (HA) epitope into the extracellular region of GluA1. They observed that when oocytes were injected with 2, 1, or 0.1 ng of GluA1 cRNA, both the amount of GluA1 on the cell surface and the currents triggered by L-glu were reduced, while co-injection of stargazin cRNA with 0.1 ng GluA1 significantly enhanced glutamate-evoked currents. Notably, the increase in current was substantially greater than the increase in GluA1 surface expression, suggesting that stargazin enhances GluA1 function through a mechanism that is not solely dependent on receptor trafficking (Tomita et al., 2005).

Structurally, TARPs are composed of four transmembrane domains (TM1-TM4), with an intracellular N-terminal domain (NTD) preceding TM1. The extracellular domain is composed of β-strands, an extracellular helix, four flexible loops, and an intracellular C-terminal Domain (CTD), as shown in Figure 5. The TM3 and TM4 domain of TARPs directly interacts with M1 and M4 of adjacent AMPAR subunits (Twomey et al., 2016). As described earlier, AMPAR has a twofold symmetry which gives rise to two distinct TARP binding sites referred to as A'/C' and B'/D' sites (Zhao et al., 2016). This site has no relation to the A/C and B/D subunit positions defined within the AMPAR tetramer. The A'/C' binding sites are located beneath the ABD dimers and are more sterically constrained compared to the B'/D' binding sites, which are located below the ABD dimers. As a result, the specific binding position of TARPs within the AMPAR complex may influence how they modulate receptor function ().

TARPs act as a positive modulator of synaptic transmission; they act by slowing the desensitization and deactivation kinetics of AMPARs. The residues in the lower lobe of the AMPAR ABD are found to be critical for γ-2 mediated gating modulation and are hypothesized to interact with the extracellular domain of TARPs, slowing desensitization kinetics of GluA2 AMPARs (Twomey et al., 2019b). In type I TARPs, the residues within the β1–β2 loop of the extracellular domain are also responsible for slowing receptor desensitization ().

Germ cell-specific gene 1-like (GSG1L) protein

GSG1L is another widely studied auxiliary subunit known to interact with GluA1 and GluA2 subunits of AMPAR (). GSG1L shows some structural similarity to TARPs, as shown in Figure 5. GSG1L expresses during later phase of development and is expressed in region specific manner in brain, GSG1L can either co-assemble with TARPs, Cornichons or as the sole auxiliary subunits. GSG1L slows the recovery of AMPARs from desensitized state through evolutionarily-conserved allosteric site unique to GSG1L (Perozzo et al., 2023). Schwenk et al. (2012) also found that this protein is associated with GluA2- or GluA4-containing AMPARs in dendritic spines of hippocampal pyramidal neurons, giving a clue that these proteins may possibly have a role in synaptic transmission. Shanks et al. (2012) found that GSG1L negatively modulates synaptic transmission; it works by stabilizing the desensitized state (Schwenk et al., 2012). Studies have shown that the two GSG1L subunits bind to the M1 and M4 of adjacent AMPARs, preferentially to the B0/D0 site (Twomey et al., 2019a, 2017).

Cornichon (CNIHs)

Proteomic analyses have identified four cornichon family proteins (CNIH1-4 4); however, only CNIH2 and CNIH3 have been shown to associate with AMPAR (AMPAR) subunits (Schwenk et al., 2009). showed that CNIH-2/-3 selectively bind to GluA1 in hippocampal neurons, enhancing surface expression of GluA1A2 receptors (). Cornichon has four transmembrane domains with both N and C termini facing the extracellular space, as shown in Figure 5. CNIH2 is expressed abundantly in the Hippocampus, striatum, and cortex (Schwenk et al., 2014). Previous studies in Drosophila, chickens, and cultured cells have characterized cornichon and its homologs as cargo exporters in the endoplasmic reticulum (ER) for members of the transforming growth factor α (TGFα) family (; ). Based on these findings, Shi and colleagues examined the potential role of CNIH2 in AMPAR trafficking. Their study demonstrated that CNIH2 facilitates the export of AMPARs to the cell surface (Shi et al., 2010). Their findings were further supported by who found that the overexpression of CNIH-2 in HeLa and primary neurons increased the functional surface population of AMPARs. Investigation of the underlying mechanism unrevealed that the CNIH-2 subunits continuously shuttle between the endoplasmic reticulum (ER) and the Golgi apparatus. During this cycle, they pick up cargo proteins in the ER and facilitate their selective export through a coat protein complex II (COPII)-dependent mechanism (). CNIH3 and TARPs both bind to the surface formed by the M1 and M4 helices of neighboring AMPAR subunits, resulting in competition between them for the same binding site; this reduces the number of CNIH that can potentially bind with AMPARs (). Like TARPs, CNIH proteins also directly modulate AMPAR function by enhancing L-glu sensitivity and prolonging both deactivation and desensitization (Schwenk et al., 2009; ).

Cystine-knot AMPA receptor-modulating proteins (CKAMPs)

CKAMPs constitute a family of four proteins, namely CKAMP39 (shisa8), CKAMP44 (shisa9), CKAMP52 (shisa6), and CKAMP59 (shisa7). Structurally, they are classified as type I transmembrane proteins, with the cysteine-rich N-terminal domain oriented toward the extracellular space and the C-terminal domain, with a PDZ type II binding motif, facing the cytoplasm. The extracellular cysteine-rich domain and short stretch of 20 amino acids immediately downstream of the transmembrane domain is known to interact and modulate AMPARs (), while the PDZ type II binding motif act as anchoring site proteins for such as PSD95, GRIP1, MPP5, PICK1 and Lin7b (; ; ). CKAMPs family members show regional expression profiles within the brain, CKAMP39 is expressed in granule cells of the cerebellum and olfactory bulb, CKAMP44 is abundantly expressed in the dentate gyrus and the glomerular layer of the olfactory bulb, CKAMP52 is expressed in the principal cell layers of all hippocampus, and the Purkinje layer of the cerebellum, KAMP44 and CKAMP52 only colocalize with glutamatergic synapses. While CKAMP59 mRNA is expressed in the cortex, striatum, and principal cell layers of the hippocampus, the granule cell layer of the olfactory bulb (von Engelhardt, 2019). CKAMP44 enhances the sensitivity of AMPARs to L-glu, slows the rate of deactivation, accelerates desensitization, and delays recovery from the desensitized state. These effects may be due to its ability to stabilize the closed-cleft conformation of the agonist-binding domain (ABD), favoring the desensitized state (von Engelhardt et al., 2010).

Synapse differentiation-induced gene 4 (SynDIG4)/Prrt1

SynDIG4/Prrt1 is a type II transmembrane protein that is known to colocalize with AMPARs GluA1 subunit at synapses and extrasynaptic sites, modulating the AMPARs' activity. Prrt1 was initially identified as a key gene involved in synapse differentiation (; ). Prrt1 has an N-terminal domain facing the cytoplasm, a transmembrane domain, and a membrane-associated C-terminal domain as shown in Figure 5. Prrt1 is known to interact with all of the AMPAR subunits GluA1-GluA4. This interaction is mediated by the transmembrane domain and intracellular loop (Martin et al., 2021). SynDIG4 is known to act by slowing the deactivation and desensitization kinetics of AMPARs in a subunit-dependent manner. SynDIG4 Knockout mice, therefore, have shown reduced AMPAR-mediated mEPSCs (Matt et al., 2018).

Disease associated with AMPAR complexes

Auxiliary subunits of AMPAR are known to interact directly or indirectly with AMPAR subunits and several synaptic molecules that modulate receptor trafficking, localization, and gating kinetics; their dysregulation has been directly linked to the pathology of various neurological disorders.

Amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that leads to the degeneration of motor neurons projecting from the motor cortex, brainstem, and the spinal cord. Several studies have suggested that AMPARs play a major role in slow and selective neurodegeneration of motor neurons as seen in ALS. To date, riluzole—a glutamate-modulating drug with anti-excitotoxic effects—remains the only therapy shown to slow ALS progression and prolong survival by roughly 2–3 months (; ), reinforcing the notion that glutamate-driven excitotoxicity is central to ALS pathogenesis. Although NMDAR-mediated mechanisms have traditionally been implicated in glutamate-induced excitotoxicity, emerging evidence suggests that in ALS, calcium-permeable AMPARs play a predominant role in mediating neuronal excitotoxicity. The exact mechanism underlying neuronal excitotoxicity in ALS has not yet been fully understood, but it has been found that the overactivation of AMPARs causes mitochondrial Ca2+ overload, leading to mitochondrial damage and production of Reactive Oxygen Species (ROS) (Williams et al., 1997; , ). Neurons show selective vulnerability to excessive Ca2+ influx; motor neurons have lower expression of Ca2+ binding proteins, limiting their Ca2+ buffering properties, which makes them more susceptible to AMPAR-mediated excitotoxicity (Van Den Bosch et al., 2006). Permeability to Calcium by AMPARs is determined by the presence of the GluA2 subunit; its presence makes AMPARs impermeable to Ca2+ (). But as mentioned earlier in the review, GluA2-containing AMPARs have now been shown to have permeability for calcium ions (Miguez-Cabello et al., 2025). GluA2 subunit undergoes post-translational modification at the Q/R site of the M2 domain, where glutamine is substituted by arginine. It is the presence of this edited Arginine in the central position that renders calcium impermeability to the GluA2 bearing AMPARs (Seeburg and Hartner, 2003). In a study conducted by Kawahara et al., they reported a significant reduction in RNA editing at the Q/R site of the GluA2 subunits in spinal motor neurons of patients with sporadic ALS, suggesting that this alteration may contribute to the development and progression of the disease ().

Alzheimer's disease (AD)

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that predominantly impairs memory and cognitive function. The pathological hallmarks of AD include the accumulation of extracellular amyloid-β (Aβ) plaques and the formation of intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein (; ). During the early stages of AD, synaptic deterioration emerges as a key pathological feature, and AMPARs are the principal glutamate receptors that mediate fast excitatory neurotransmission. Thus, synaptic deterioration is strongly linked to the impaired function of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Dysfunction of these receptors disrupts excitatory neurotransmission and synaptic plasticity, processes that are critical for learning and memory, thereby contributing to the early cognitive deficits observed in AD (Ning et al., 2024). As discussed earlier, AMPARs are composed of GluA1-GluA4 subunits, and Aβ has been known to bind to the C-terminal tail of unedited GluA2 subunits, which leads to a reduction in the expression of surface AMPARs, weakening the strength between synapses (). The exact molecular mechanism that leads to the decrease in the expression of AMPARs has not yet been fully elucidated, but a study conducted by Zhang et al. (2018) reported that the presence of Aβ both in culture and brain of AD patients showed enhanced ubiquitination of surface AMPARs, facilitating receptor internalization and degradation causing LTD. Enhanced ubiquitination is mediated by upregulation of Nedd4, an E3 ligase, and downregulation of deubiquitinase USP46 (Zhang et al., 2018). Aβ not only alters the ubiquitination of AMPARs but is also known to alter the acetylation of AMPARs in AD conditions. Normally, AMPARs are subjected to lysine acetylation by p300 acetyltransferase, conferring them higher stability, reduced receptor internalization and degradation (Wang G. et al., 2017). Under AD conditions, AMPARs are hypoacetylated, leading to a reduction in surface AMPARs and contributing to synaptic weakening and impaired cognition, as seen in AD (O'Connor et al., 2020). In addition to ubiquitination, Aβ may also impact the surface diffusion of AMPARs. Accumulation of amyloid-β (Aβ) within neurons has been known to mislocalize and internalize the L-glu transporter in astrocytes, decreasing L-glu clearance (Matos et al., 2008; Li et al., 2009; ). Aβ also increases L-glu spillover through α7 nicotinic acetylcholine receptors (a7nAChR) (Zhang et al., 2022; ; ). This excessive L-glu leads to aberrant activation of extrasynaptic GluN2B-containing NMDARs, subsequently activating downstream Rap-p38 MAP, protein phosphatases PP1, and calcineurin, inducing AMPAR endocytosis and excitotoxicity, contributing to progressive neuronal damage as seen in AD (). The modulation of AMPARs has emerged as a promising therapeutic strategy for addressing cognitive deficits associated with AD. Preclinical studies have demonstrated the efficacy of AMPAR-positive modulators in enhancing synaptic transmission and improving memory functions. One such compound, LY451395, has been shown to act as a positive allosteric modulator of AMPARs. In animal models, systemic administration of LY451395 increased AMPAR-mediated synaptic responses in the hippocampus and significantly improved performance in memory-based behavioral tasks. However, despite promising preclinical outcomes, clinical trials in patients with mild to moderate AD failed to show significant cognitive improvement following an 8-week administration of LY451395. Nevertheless, these studies underscore the potential of AMPAR modulation in AD therapy (; ).

Epilepsy

Epilepsy ranks among the most prevalent neurological disorders worldwide. The characteristic features of Epilepsy include recurrent, unprovoked seizures resulting from brief, abnormal bursts of electrical activity in the brain that alter behavior, consciousness, cognition, and/or movement. These episodes reflect a temporary disruption of the brain's excitatory-inhibitory balance, detectable through EEG monitoring. (Milligan, 2021). Elevated levels of extracellular L-glu concentrations have been seen in epilepsy patients (Sarlo and Holton, 2021). Evidence shows that AMPAR antagonists effectively suppress seizures, indicating an important role of glutamatergic signaling in epilepsy pathogenesis (; ; ). Genetic screening of epilepsy patients has identified Nedd4-2 mutations, an epilepsy-associated gene encoding a ubiquitin E3 ligase that regulates neuronal activity via GluA1 ubiquitination. All three identified missense mutations disrupt GluA1 ubiquitination, failing to reduce surface GluA1 levels and also spontaneous neuronal activity, explaining the heightened electrical activity in the brain (Zhu et al., 2017). Studies also showed a decreased number of AMPARs in epileptic patients compared to normal people (). Also, excessive glutamate receptor activation elevates intracellular calcium levels, contributing significantly to neuronal death in epilepsy. After a neurologically adverse incident like an epileptic seizure, GluA2 AMPAR expression drops, promoting the formation of calcium-permeable, GluA2-lacking AMPARs that may amplify glutamate-mediated neurotoxicity (Lorgen et al., 2017).

Limbic encephalitis and Rasmussen's encephalitis

Limbic encephalitis involves autoimmune-mediated inflammation targeting the limbic system and other brain regions. Some limbic encephalitis patients harbor autoantibodies against GluA1, GluA2, or GluA1/GluA2 subunits. These autoantibodies target the N-terminal (NTD) and ligand-binding (ABD) domains of GluA1/2 without binding specific epitopes (). Anti-GluA1/2 autoantibodies promote synaptic AMPAR internalization, causing chronic AMPAR dysfunction and impaired synaptic plasticity (Peng et al., 2015; ; ). Disrupted synaptic plasticity underlies the memory deficits observed in mouse models infused with patient-derived anti-GluA2 autoantibodies (). While these antibodies primarily target GluA1 and GluA2 epitopes, they also reduce synaptic levels of GluA3-containing AMPARs (e.g., GluA2/3 heteromers) (Peng et al., 2015; ).

Anti-GluA3 autoantibodies were initially identified in a Rasmussen's encephalitis patient (Rogers et al., 1994), a severe pediatric condition characterized by seizures, hemiparesis, motor deficits, and cognitive decline (). These antibodies have since been associated with additional seizure disorders (Levite, 2014). Multiple anti-GluA3 autoantibodies, including those from Rasmussen's encephalitis, bind to the N-terminal domain (NTD) residues 372–395 of GluA3 (Mantegazza et al., 2002; Levite et al., 1999; ). These antibodies function as positive allosteric modulators, exerting pathogenic effects through both direct agonist activity and complement-dependent cytotoxicity (Levite et al., 1999; Whitney and McNamara, 2000; Twyman et al., 1995; ; ; ). Animal models immunized with peptides containing the anti-GluA3 epitope develop behavioral impairments and neuronal degeneration (; , ). Current standard treatments for Rasmussen's encephalitis remain immunosuppressive therapy and surgical hemispherectomy of the affected cerebral hemisphere.

Autism spectrum disorder (ASD)

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder affecting people's ability to communicate, interact, and learn. Genes implicated in ASD are often involved in fundamental cellular pathways, including protein synthesis, cell proliferation, and synaptic function, highlighting the molecular complexity underlying the pathophysiology of ASD (Ozonoff et al., 2005; Lin et al., 2016; ). ASD has become a widespread and socially significant neurodevelopmental condition, currently affecting approximately 1.5% of the population (Lyall et al., 2017; ).

The causes of ASD consist of a wide range of contributing factors, such as de-novo mutations and microdeletions of GRIA2 gene (Rylaarsdam and Guemez-Gamboa, 2019; Salpietro et al., 2019); environmental and acquired influences during the pre-, peri-, and postnatal periods (Wang C. et al., 2017); and the polygenic co-inheritance of, asymptomatic haplotypes or polymorphisms that may converge to disrupt neural circuit homeostasis (Rubenstein and Merzenich, 2003). Among these are the structural components critical to synaptic integrity and brain circuit function. Particularly those involving AMPAR-mediated neurotransmission. Some pathways demonstrate selective enrichment in cerebro-cerebellar regions, hinting at their role in ASD (; ). Findings have shown a general upregulation of AMPAR mRNA transcripts, coupled with a selective reduction in AMPAR protein levels within the cerebellum in individuals affected by autism (Purcell et al., 2001). Studies have also identified a potential molecular pathway underlying this disruption: loss of function in UBE3A, a gene implicated in both autism and Angelman syndrome, was shown to increase AMPAR internalization, thereby attenuating synaptic AMPAR availability and reducing LTP (). Genetic mutations in P-Rex1, a gene involved in regulating AMPAR endocytosis, have been identified in individuals with autism, and preclinical models lacking this gene exhibit behavioral phenotypes consistent with core features of ASD, including social deficits and reduced behavioral flexibility (Li et al., 2015). Neurobeachin, a gene identified in autism-associated cohorts, has revealed pronounced disruptions in dendritic spine morphology accompanied by a reduction in miniature excitatory post-synaptic currents (mEPSCs) (Niesmann et al., 2011). In contrast, studies of Rbm8a, a gene involved in non-sense-mediated mRNA decay and similarly linked to autism, have demonstrated abnormally elevated mEPSC frequency (). Genetic mouse models with targeted deletions of synaptic scaffolding proteins such as Shank3 exhibit a significant reduction in AMPAR-mediated current, contributing to the synaptic deficit. This finding supports the hypothesis that altered AMPAR signaling contributes to the neurodevelopmental and behavioral phenotypes observed in ASD (; ). These findings hint toward a role of AMPARs in ASD pathogenesis due to their crucial role in synaptic transmission and generation of EPSCs.

Perspectives

Glutamatergic receptors, particularly AMPARs, constitute one of the most critical molecular families in the central nervous system. Their biophysical properties, subunit composition, interaction partners, and membrane dynamics exert a direct influence on synaptic function, plasticity, and the pathophysiology of numerous brain-related disorders. Changes in AMPAR expression, trafficking, and clustering are increasingly recognized as molecular hallmarks of neurodevelopmental, neuropsychiatric, and neurodegenerative diseases. Over the past three decades, a substantial body of knowledge has accumulated regarding the molecular composition and biochemical behavior of AMPARs. These studies have identified a range of endogenous ligands, mapped their expression profiles across brain regions, and explored their interaction networks through genomic, proteomic, and biochemical paradigms. Classical structural and biophysical approaches, including crystallography, electrophysiology, and fluorescence-based imaging, have offered deep insight into AMPAR function at synaptic membranes. However, recent studies are revealing a new layer of complexity, with a growing emphasis on the spatial distribution of AMPARs within sub-synaptic and extrasynaptic domains, their dynamic trafficking kinetics, and the emergent principles of allosteric gating.

One emerging theme is the spatial regulation of AMPAR clustering at nanodomains, which modulates both the amplitude and frequency of excitatory post-synaptic currents. Subsynaptic organization is now known to be governed by multiple mechanisms, including activity-dependent anchoring, scaffolding interactions, and homeostatic scaling. These processes are not merely passive; they exert non-linear effects on receptor gating, ligand binding, and signal integration. For instance, changes in receptor density and localization in nanodomains influence ligand binding kinetics, desensitization rates, and synaptic current summation, collectively reshaping synaptic strength and plasticity. Understanding this spatial and kinetic heterogeneity is increasingly important for future therapeutic targeting. The complexity of AMPAR function cannot be captured by traditional pharmacology alone. Future strategies will likely require multi-pronged approaches that integrate molecular modeling, AI-guided drug discovery, and high-throughput screening platforms. These methods can be informed by detailed structural insights from cryo-electron microscopy and super-resolution imaging and validated using patch-clamp electrophysiology and optogenetic assays in physiologically relevant models.

The mounting evidence points to AMPARs as early molecular transducers of activity-dependent synaptic changes. As such, they represent promising targets for therapeutic modulation in early-stage cognitive dysfunction and neurodegenerative disease. One forward-looking direction involves engineering synthetic ligands that can selectively modulate AMPAR activity in a brain region-specific manner, effectively designing chemical switches to silence or activate particular excitatory circuits. Additionally, advances in genome editing technologies such as CRISPR-Cas9 have opened new possibilities to modify AMPAR genes in the adult brain with cell-type and region-specific precision. This raises the exciting potential for molecular engineering of customized receptor variants that could restore or tune synaptic function in disease contexts. By combining synthetic biology, structural pharmacology, and next-generation imaging and editing tools, the next decade may offer transformative strategies for regulating AMPAR activity with unprecedented precision and efficacy in the context of brain disorders.

Statements

Author contributions

FF: Writing – review & editing, Writing – original draft. DC: Writing – review & editing, Writing – original draft. DN: Writing – review & editing, Writing – original draft.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. FF and DC acknowledge funding from Indian Institute of Science through Ministry of Education, India and Council of Scientific and industrial Research India, respectively. DN acknowledges the senior research grant from DBT Wellcome Trust India Alliance (IA/S/23/2/507005) and Cores Research grant from Anusandhan National Research Foundation (CRG/2022/002726) and Intramural support from IISc.

Acknowledgments

Figures were created in BioRender by Nair (2025).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that Gen AI was used in the creation of this manuscript. Authors used language models solely to correct grammar and spelling. No content was generated by AI. The author(s) take full responsibility for the use of AI tools in the preparation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    AlachkarA.JiangD.HarrisonM.ZhouY.ChenG.MaoY. (2013). An EJC factor RBM8a regulates anxiety behaviors. Curr. Mol. Med.13, 887899. 10.2174/15665240113139990019

  • 2

    AlbersteinR.GreyR.ZimmetA.SimmonsD. K.MayerM. L. (2015). Glycine activated ion channel subunits encoded by ctenophore glutamate receptor genes. Proc. Natl. Acad. Sci. U. S. A.112, E6048E6057. 10.1073/pnas.1513771112

  • 3

    Al-HallaqR. A.JarabekB. R.FuZ.ViciniS.WolfeB. B.YasudaR. P. (2002). Association of NR3A with the N-methyl-D-aspartate receptor NR1 and NR2 subunits. Mol. Pharmacol.62, 11191127. 10.1124/mol.62.5.1119

  • 4

    AndersonC. M.SwansonR. A. (2000). Astrocyte glutamate transport: review of properties, regulation, physiological functions. Glia32, 114. 10.1002/1098-1136(200010)32:%3C1::AID-GLIA10%3E3.0.CO;2-W

  • 5

    AnggonoV.HuganirR. L. (2012). Regulation of AMPA receptor trafficking and synaptic plasticity. Curr. Opin. Neurobiol.22, 461469. 10.1016/j.conb.2011.12.006

  • 6

    AnwylR. (1999). Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res. Brain Res. Rev.29, 83120. 10.1016/S0165-0173(98)00050-2

  • 7

    ArchibaldK.PerryM. J.MolnárE.HenleyJ. M. (1998). Surface expression and metabolic half-life of AMPA receptors in cultured rat cerebellar granule cells. Neuropharmacology37, 13451353. 10.1016/S0028-3908(98)00135-X

  • 8

    ArinaminpathyY.BigginP. C.ShrivastavaI. H.SansomM. S. (2003). A prokaryotic glutamate receptor: homology modelling and molecular dynamics simulations of GluR0. FEBS Lett.553, 321327. 10.1016/S0014-5793(03)01036-6

  • 9

    AyalonG.SegevE.ElgavishS.Stern-BachY. (2005). Two regions in the N-terminal domain of ionotropic glutamate receptor 3 form the subunit oligomerization interfaces that control subtype-specific receptor assembly. J. Biol. Chem.280, 1505315060. 10.1074/jbc.M408413200

  • 10

    AyalonG.Stern-BachY. (2001). Functional assembly of AMPA and kainate receptors is mediated by several discrete protein-protein interactions. Neuron31, 103113. 10.1016/S0896-6273(01)00333-6

  • 11

    BabaeiP. (2021). NMDA and AMPA receptors dysregulation in Alzheimer's disease. Eur. J. Pharmacol.908:174310. 10.1016/j.ejphar.2021.174310

  • 12

    BagniC.ZukinR. S. A. (2019). Synaptic perspective of fragile X syndrome and autism spectrum disorders. Neuron101, 10701088. 10.1016/j.neuron.2019.02.041

  • 13

    BainsM.HallE. D. (2012). Antioxidant therapies in traumatic brain and spinal cord injury. Biochim. Biophys. Acta1822, 675684. 10.1016/j.bbadis.2011.10.017

  • 14

    Barker-HaliskiM.WhiteH. S. (2015). glutamatergic mechanisms associated with seizures and epilepsy. Cold Spring Harb. Perspect. Med.5:a022863. 10.1101/cshperspect.a022863

  • 15

    BarnesJ. M.HenleyJ. M. (1992). Molecular characteristics of excitatory amino acid receptors. Prog. Neurobiol.39, 113133. 10.1016/0301-0082(92)90007-2

  • 16

    BayésÀ.CollinsM. O.GaltreyC. M.SimonnetC.RoyM.CroningM. D.et al. (2014). Human post-mortem synapse proteome integrity screening for proteomic studies of post-synaptic complexes. Mol. Brain7:88. 10.1186/s13041-014-0088-4

  • 17

    BedoukianM. A.WeeksA. M.PartinK. M. (2006). Different domains of the AMPA receptor direct stargazin-mediated trafficking and stargazin-mediated modulation of kinetics. J. Biol. Chem.281, 2390823921. 10.1074/jbc.M600679200

  • 18

    BennettB. D.KimballE. H.GaoM.OsterhoutR.Van DienS. J.RabinowitzJ. D. (2009). Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat. Chem. Biol.5, 593599. 10.1038/nchembio.186

  • 19

    BensimonG.LacomblezL.MeiningerV. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med.330, 585591. 10.1056/NEJM199403033300901

  • 20

    BerglesD. E.RobertsJ. D.SomogyiP.JahrC. E. (2000). Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. Nature405, 187191. 10.1038/35012083

  • 21

    BevanS.MilediR.GramppW. (1973). Induced transmitter release from Schwann cells and its suppression by actinomycin D. Nat. New Biol.241, 8586. 10.1038/newbio241085a0

  • 22

    BhattacharyyaS. (2016). Inside story of group I metabotropic glutamate receptors (mGluRs). Int. J. Biochem. Cell Biol. 77(Pt B), 205212. 10.1016/j.biocel.2016.03.003

  • 23

    BienC. G.GranataT.AntozziC.CrossJ. H.DulacO.KurthenM.et al. (2005). Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain128(Pt 3), 454471. 10.1093/brain/awh415

  • 24

    BökelC.DassS.Wilsch-BräuningerM.RothS. (2006). Drosophila Cornichon acts as cargo receptor for ER export of the TGFalpha-like growth factor Gurken. Development133, 459470. 10.1242/dev.02219

  • 25

    BowieD. (2012). Redefining the classification of AMPA-selective ionotropic glutamate receptors. J. Physiol.590, 4961. 10.1113/jphysiol.2011.221689

  • 26

    BrooksB. R. (2009). Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann. Neurol.65(Suppl. 1), S17S23. 10.1002/ana.21544

  • 27

    BurnashevN.MonyerH.SeeburgP. H.SakmannB. (1992). Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron8, 189198. 10.1016/0896-6273(92)90120-3

  • 28

    BurnashevN.ZhouZ.NeherE.SakmannB. (1995). Fractional calcium currents through recombinant GluR channels of the NMDA, AMPA and kainate receptor subtypes. J. Physiol. 485 (Pt 2), 403418. 10.1113/jphysiol.1995.sp020738

  • 29

    CarlsonN. G.GahringL. C.TwymanR. E.RogersS. W. (1997). Identification of amino acids in the glutamate receptor, GluR3, important for antibody-binding and receptor-specific activation. J. Biol. Chem.272, 1129511301. 10.1074/jbc.272.17.11295

  • 30

    CarriedoS. G.SensiS. L.YinH. Z.WeissJ. H. (2000). AMPA exposures induce mitochondrial Ca(2+) overload and ROS generation in spinal motor neurons in vitro. J. Neurosci.20, 240250. 10.1523/JNEUROSCI.20-01-00240.2000

  • 31

    CarriedoS. G.YinH. Z.SensiS. L.WeissJ. H. (1998). Rapid Ca2+ entry through Ca2+-permeable AMPA/Kainate channels triggers marked intracellular Ca2+ rises and consequent oxygen radical production. J. Neurosci.18, 77277738. 10.1523/JNEUROSCI.18-19-07727.1998

  • 32

    CastilloP. E.MalenkaR. C.NicollR. A. (1997). Kainate receptors mediate a slow postsynaptic current in hippocampal CA3 neurons. Nature388, 182186. 10.1038/40645

  • 33

    CastroC. P.PiscopoD.NakagawaT.DerynckR. (2007). Cornichon regulates transport and secretion of TGFalpha-related proteins in metazoan cells. J. Cell Sci.120(Pt 14), 24542466. 10.1242/jcs.004200

  • 34

    CelliR.FornaiF. (2021). Targeting ionotropic glutamate receptors in the treatment of epilepsy. Curr. Neuropharmacol.19, 747765. 10.2174/1570159X18666200831154658

  • 35

    CertainN.GanQ.BennettJ.HsiehH.WollmuthL. P. (2023). Differential regulation of tetramerization of the AMPA receptor glutamate-gated ion channel by auxiliary subunits. J. Biol. Chem. 299;105227. 10.1016/j.jbc.2023.105227

  • 36

    ChangP.AugustinK.BoddumK.WilliamsS.SunM.TerschakJ. A.et al. (2016). Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain139(Pt 2), 431443. 10.1093/brain/awv325

  • 37

    ChangP. K.VerbichD.McKinneyR. A. (2012). AMPA receptors as drug targets in neurological disease–advantages, caveats, future outlook. Eur. J. Neurosci.35, 19081916. 10.1111/j.1460-9568.2012.08165.x

  • 38

    ChappellA. S.GonzalesC.WilliamsJ.WitteM. M.MohsR. C.SperlingR. (2007). AMPA potentiator treatment of cognitive deficits in Alzheimer's disease. Neurology68, 10081012. 10.1212/01.wnl.0000260240.46070.7c

  • 39

    ChaterT. E.GodaY. (2022). The shaping of AMPA receptor surface distribution by neuronal activity. Front. Synaptic Neurosci.14:833782. 10.3389/fnsyn.2022.833782

  • 40

    ChattertonJ. E.AwobuluyiM.PremkumarL. S.TakahashiH.TalantovaM.ShinY.et al. (2002). Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature415, 793798. 10.1038/nature715

  • 41

    ChenG. Q.CuiC.MayerM. L.GouauxE. (1999). Functional characterization of a potassium-selective prokaryotic glutamate receptor. Nature402, 817821. 10.1038/45568

  • 42

    ChenL.ChetkovichD. M.PetraliaR. S.SweeneyN. T.KawasakiY.WentholdR. J.et al. (2000). Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms. Nature408, 936943. 10.1038/35050030

  • 43

    ChetkovichD. M.ChenL.StockerT. J.NicollR. A.BredtD. S. (2002). Phosphorylation of the postsynaptic density-95 (PSD-95)/discs large/zona occludens-1 binding site of stargazin regulates binding to PSD-95 and synaptic targeting of AMPA receptors. J. Neurosci.22, 57915796. 10.1523/JNEUROSCI.22-14-05791.2002

  • 44

    ChiuJ.DeSalleR.LamH. M.MeiselL.CoruzziG. (1999). Molecular evolution of glutamate receptors: a primitive signaling mechanism that existed before plants and animals diverged. Mol. Biol. Evol.16, 826838. 10.1093/oxfordjournals.molbev.a026167

  • 45

    ChoiJ.KoJ.ParkE.LeeJ. R.YoonJ.LimS.et al. (2002). Phosphorylation of stargazin by protein kinase A regulates its interaction with PSD-95. J. Biol. Chem.277, 1235912363. 10.1074/jbc.M200528200

  • 46

    ChowdhuryS.ShepherdJ. D.OkunoH.LyfordG.PetraliaR. S.PlathN.et al. (2006). Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking. Neuron52, 445459. 10.1016/j.neuron.2006.08.033

  • 47

    CitriA.MalenkaR. C. (2008). Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology33, 1841. 10.1038/sj.npp.1301559

  • 48

    Cohen-Kashi MalinaK.GanorY.LeviteM.TeichbergV. I. (2006). Autoantibodies against an extracellular peptide of the GluR3 subtype of AMPA receptors activate both homomeric and heteromeric AMPA receptor channels. Neurochem. Res.31, 11811190. 10.1007/s11064-006-9143-6

  • 49

    ConnP. J.PinJ. P. (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol.37, 205237. 10.1146/annurev.pharmtox.37.1.205

  • 50

    CoombsI. D.Cull-CandyS. G. (2009). Transmembrane AMPA receptor regulatory proteins and AMPA receptor function in the cerebellum. Neuroscience162, 656665. 10.1016/j.neuroscience.2009.01.004

  • 51

    CoombsM. A.Addington-HallJ.Long-SutehallT. (2012). Challenges in transition from intervention to end of life care in intensive care: a qualitative study. Int. J. Nurs. Stud.49, 519527. 10.1016/j.ijnurstu.2011.10.019

  • 52

    CorteseB. M.PhanK. L. (2005). The role of glutamate in anxiety and related disorders. CNS Spectr.10, 820830. 10.1017/S1092852900010427

  • 53

    CoutinhoV.KnopfelT. (2002). Metabotropic glutamate receptors: electrical and chemical signaling properties. Neuroscientist8, 551561. 10.1177/1073858402238514

  • 54

    CuadraA. E.KuoS. H.KawasakiY.BredtD. S.ChetkovichD. M. (2004). AMPA receptor synaptic targeting regulated by stargazin interactions with the Golgi-resident PDZ protein nPIST. J. Neurosci.24, 74917502. 10.1523/JNEUROSCI.1255-04.2004

  • 55

    CuiC.MayerM. L. (1999). Heteromeric kainate receptors formed by the coassembly of GluR5, GluR6, and GluR7. J. Neurosci.19, 82818291. 10.1523/JNEUROSCI.19-19-08281.1999

  • 56

    CurtisD. R.PhillisJ. W.WatkinsJ. C. (1959). Chemical excitation of spinal neurones. Nature183, 611612. 10.1038/183611a0

  • 57

    CurtisD. R.PhillisJ. W.WatkinsJ. C. (1960). The chemical excitation of spinal neurones by certain acidic amino acids. J. Physiol.150, 656682. 10.1113/jphysiol.1960.sp006410

  • 58

    DanboltN. C. (2001). Glutamate uptake. Prog. Neurobiol.65, 1105. 10.1016/S0301-0082(00)00067-8

  • 59

    DaniA.HuangB.BerganJ.DulacC.ZhuangX. (2010). Superresolution imaging of chemical synapses in the brain. Neuron68, 843856. 10.1016/j.neuron.2010.11.021

  • 60

    De BortoliS.TeardoE.SzabòI.MorosinottoT.AlboresiA. (2016). Evolutionary insight into the ionotropic glutamate receptor superfamily of photosynthetic organisms. Biophys. Chem.218, 1426. 10.1016/j.bpc.2016.07.004

  • 61

    de Leon-LopezC. A. M.Carretero-ReyM.KhanZ. U. (2025). AMPA receptors in synaptic plasticity, memory function, brain diseases. Cell. Mol. Neurobiol.45:14. 10.1007/s10571-024-01529-7

  • 62

    DennisM. J.MilediR. (1974). Electrically induced release of acetylcholine from denervated Schwann cells. J. Physiol.237, 431452. 10.1113/jphysiol.1974.sp010490

  • 63

    DieringG. H.GustinaA. S.HuganirR. L. (2014). PKA-GluA1 coupling via AKAP5 controls AMPA receptor phosphorylation and cell-surface targeting during bidirectional homeostatic plasticity. Neuron84, 790805. 10.1016/j.neuron.2014.09.024

  • 64

    DrachmanD. A. (2005). Do we have brain to spare?Neurology64, 20042005. 10.1212/01.WNL.0000166914.38327.BB

  • 65

    Ebrahimi-FakhariD.SahinM. (2015). Autism and the synapse: emerging mechanisms and mechanism-based therapies. Curr. Opin. Neurol.28, 91102. 10.1097/WCO.0000000000000186

  • 66

    EhlersM. D.FungE. T.O'BrienR. J.HuganirR. L. (1998). Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J. Neurosci.18, 720730. 10.1523/JNEUROSCI.18-02-00720.1998

  • 67

    EhlersM. D.HeineM.GrocL.LeeM. C.ChoquetD. (2007). Diffusional trapping of GluR1 AMPA receptors by input-specific synaptic activity. Neuron54, 447460. 10.1016/j.neuron.2007.04.010

  • 68

    EiroT.MiyazakiT.HatanoM.NakajimaW.ArisawaT.TakadaY.et al. (2023). Dynamics of AMPA receptors regulate epileptogenesis in patients with epilepsy. Cell Rep. Med.4:101020. 10.1016/j.xcrm.2023.101020

  • 69

    ErecinskaM.SilverI. A. (1990). Metabolism and role of glutamate in mammalian brain. Prog. Neurobiol.35, 245296. 10.1016/0301-0082(90)90013-7

  • 70

    ErregerK.ChenP. E.WyllieD. J.TraynelisS. F. (2004). Glutamate receptor gating. Crit. Rev. Neurobiol.16, 187224. 10.1615/CritRevNeurobiol.v16.i3.10

  • 71

    EvansA. J.GurungS.HenleyJ. M.NakamuraY.WilkinsonK. A. (2019). Exciting times: new advances towards understanding the regulation and roles of kainate receptors. Neurochem. Res.44, 572584. 10.1007/s11064-017-2450-2

  • 72

    FairmanW. A.AmaraS. G. (1999). Functional diversity of excitatory amino acid transporters: ion channel and transport modes. Am. J. Physiol.277, F481F486. 10.1152/ajprenal.1999.277.4.F481

  • 73

    FelderC. B.GraulR. C.LeeA. Y.MerkleH. P.SadeeW. (1999). The Venus flytrap of periplasmic binding proteins: an ancient protein module present in multiple drug receptors. AAPS PharmSci.1:E2. 10.1208/ps010202

  • 74

    FiorilloC. D.WilliamsJ. T. (1998). Glutamate mediates an inhibitory postsynaptic potential in dopamine neurons. Nature394, 7882. 10.1038/27919

  • 75

    FiuzaM.RostoskyC. M.ParkinsonG. T.BygraveA. M.HalemaniN.BaptistaM.et al. (2017). PICK1 regulates AMPA receptor endocytosis via direct interactions with AP2 alpha-appendage and dynamin. J. Cell Biol.216, 33233338. 10.1083/jcb.201701034

  • 76

    FonnumF. (1984). Glutamate: a neurotransmitter in mammalian brain. J. Neurochem.42, 111. 10.1111/j.1471-4159.1984.tb09689.x

  • 77

    FordeB. G.LeaP. J. (2007). Glutamate in plants: metabolism, regulation, and signalling. J. Exp. Bot.58, 23392358. 10.1093/jxb/erm121

  • 78

    FordeB. G.RobertsM. R. (2014). Glutamate receptor-like channels in plants: a role as amino acid sensors in plant defence?F1000Prime Rep.6:37. 10.12703/P6-37

  • 79

    FukataY.DimitrovA.BoncompainG.VielemeyerO.PerezF.FukataM. (2013). Local palmitoylation cycles define activity-regulated postsynaptic subdomains. J. Cell Biol.202, 145161. 10.1083/jcb.201302071

  • 80

    FukataY.FukataM.MacGillavryH. D.NairD.HosyE. (2024). Celebrating the birthday of AMPA receptor nanodomains: illuminating the nanoscale organization of excitatory synapses with 10 nanocandles. J. Neurosci.44:e2104232024. 10.1523/JNEUROSCI.2104-23.2024

  • 81

    GanorY.Goldberg-SternH.BlankM.ShoenfeldY.DobryninaL. A.KalashnikovaL.et al. (2005a). Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome. Autoimmunity38, 417424. 10.1080/08916930500246339

  • 82

    GanorY.Goldberg-SternH.CohenR.TeichbergV.LeviteM. (2014). Glutamate receptor antibodies directed against AMPA receptors subunit 3 peptide B (GluR3B) can be produced in DBA/2J mice, lower seizure threshold and induce abnormal behavior. Psychoneuroendocrinology42, 106117. 10.1016/j.psyneuen.2014.01.005

  • 83

    GanorY.GottliebM.EilamR.OtmyH.TeichbergV. I.LeviteM. (2005b). Immunization with the glutamate receptor-derived peptide GluR3B induces neuronal death and reactive gliosis, but confers partial protection from pentylenetetrazole-induced seizures. Exp. Neurol.195, 92102. 10.1016/j.expneurol.2005.04.002

  • 84

    GerM. F.RendonG.TilsonJ. L.JakobssonE. (2010). Domain-based identification and analysis of glutamate receptor ion channels and their relatives in prokaryotes. PLoS ONE5:e12827. 10.1371/journal.pone.0012827

  • 85

    GleichmanA. J.PanzerJ. A.BaumannB. H.DalmauJ.LynchD. R. (2014). Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis. Ann. Clin. Transl. Neurol.1, 180189. 10.1002/acn3.43

  • 86

    GlennerG. G.WongC. W. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun.120, 885890. 10.1016/S0006-291X(84)80190-4

  • 87

    GoelA.XuL. W.SnyderK. P.SongL.Goenaga-VazquezY.MegillA.et al. (2011). Phosphorylation of AMPA receptors is required for sensory deprivation-induced homeostatic synaptic plasticity. PLoS ONE6:e18264. 10.1371/journal.pone.0018264

  • 88

    Goldberg-SternH.GanorY.CohenR.PollakL.TeichbergV.LeviteM. (2014). Glutamate receptor antibodies directed against AMPA receptors subunit 3 peptide B (GluR3B) associate with some cognitive/psychiatric/behavioral abnormalities in epilepsy patients. Psychoneuroendocrinology40, 221231. 10.1016/j.psyneuen.2013.11.007

  • 89

    GotoH.WatanabeK.AraragiN.KageyamaR.TanakaK.KurokiY.et al. (2009). The identification and functional implications of human-specific “fixed” amino acid substitutions in the glutamate receptor family. BMC Evol. Biol.9:224. 10.1186/1471-2148-9-224

  • 90

    GreerP. L.HanayamaR.BloodgoodB. L.MardinlyA. R.LiptonD. M.FlavellS. W.et al. (2010). The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell140, 704716. 10.1016/j.cell.2010.01.026

  • 91

    GregerI. H.WatsonJ. F.Cull-CandyS. G. (2017). Structural and functional architecture of AMPA-type glutamate receptors and their auxiliary proteins. Neuron94, 713730. 10.1016/j.neuron.2017.04.009

  • 92

    GuntupalliS.WidagdoJ.AnggonoV. (2016). Amyloid-beta-induced dysregulation of AMPA receptor trafficking. Neural. Plast.2016:3204519. 10.1155/2016/3204519

  • 93

    HafnerA. S.PennA. C.Grillo-BoschD.RetailleauN.PoujolC.PhilippatA.et al. (2015). Lengthening of the stargazin cytoplasmic tail increases synaptic transmission by promoting interaction to deeper domains of PSD-95. Neuron86, 475489. 10.1016/j.neuron.2015.03.013

  • 94

    HanadaT. (2020). Ionotropic Glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors. Biomolecules10:464. 10.3390/biom10030464

  • 95

    HansenK. B.WollmuthL. P.BowieD.FurukawaH.MennitiF. S.SobolevskyA. I.et al. (2021). Structure, function, and pharmacology of glutamate receptor ion channels. Pharmacol. Rev.73, 298487. 10.1124/pharmrev.120.000131

  • 96

    HardyJ. A.HigginsG. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science256, 184185. 10.1126/science.1566067

  • 97

    HarmelN.CokicB.ZollesG.BerkefeldH.MauricV.FaklerB.et al. (2012). AMPA receptors commandeer an ancient cargo exporter for use as an auxiliary subunit for signaling. PLoS ONE7:e30681. 10.1371/journal.pone.0030681

  • 98

    HascupK. N.HascupE. R. (2016). Soluble amyloid-beta42 stimulates glutamate release through activation of the alpha7 nicotinic acetylcholine receptor. J. Alzheimers. Dis.53, 337347. 10.3233/JAD-160041

  • 99

    HaselmannH.MannaraF.WernerC.PlanagumàJ.Miguez-CabelloF.SchmidlL.et al. (2018). Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction. Neuron100, 91105.e9. 10.1016/j.neuron.2018.07.048

  • 100

    HawkenN. M.ZaikaE. I.NakagawaT. (2017). Engineering defined membrane-embedded elements of AMPA receptor induces opposing gating modulation by cornichon 3 and stargazin. J. Physiol.595, 65176539. 10.1113/JP274897

  • 101

    HeX. P.PatelM.WhitneyK. D.JanumpalliS.TennerA.McNamaraJ. O. (1998). Glutamate receptor GluR3 antibodies and death of cortical cells. Neuron20, 153163. 10.1016/S0896-6273(00)80443-2

  • 102

    HebbD. O. (2005). The Organization of Behavior: A Neuropsychological Theory, 1st Edn. New York, NY: Psychology Press. 10.4324/9781410612403

  • 103

    HeineM.GrocL.FrischknechtR.BéïqueJ. C.LounisB.RumbaughG.et al. (2008). Surface mobility of postsynaptic AMPARs tunes synaptic transmission. Science320, 201205. 10.1126/science.1152089

  • 104

    HenleyJ. M.AmbrosiniA.Krogsgaard-LarsenP.BarnardE. A. (1989). Evidence for a single glutamate receptor of the ionotropic kainate/quisqualate type. New Biol.1, 153158.

  • 105

    HerbA.BurnashevN.WernerP.SakmannB.WisdenW.SeeburgP. H. (1992). The KA-2 subunit of excitatory amino acid receptors shows widespread expression in brain and forms ion channels with distantly related subunits. Neuron8, 775785. 10.1016/0896-6273(92)90098-X

  • 106

    HerguedasB.KriegerJ.GregerI. H. (2013). Receptor heteromeric assembly-how it works and why it matters: the case of ionotropic glutamate receptors. Prog. Mol. Biol. Transl. Sci.117, 361386. 10.1016/B978-0-12-386931-9.00013-1

  • 107

    HermansE.ChallissR. A. (2001). Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem. J.359(Pt 3), 465484. 10.1042/bj3590465

  • 108

    HerringB. E.ShiY.SuhY. H.ZhengC. Y.BlankenshipS. M.RocheK. W.et al. (2013). Cornichon proteins determine the subunit composition of synaptic AMPA receptors. Neuron77, 10831096. 10.1016/j.neuron.2013.01.017

  • 109

    HollmannM.HeinemannS. (1994). Cloned glutamate receptors. Annu. Rev. Neurosci.17, 31108. 10.1146/annurev.ne.17.030194.000335

  • 110

    HollmannM.MaronC.HeinemannS. (1994). N-glycosylation site tagging suggests a three transmembrane domain topology for the glutamate receptor GluR1. Neuron13, 13311343. 10.1016/0896-6273(94)90419-7

  • 111

    HonoreT.LauridsenJ.Krogsgaard-LarsenP. (1982). The binding of [3H]AMPA, a structural analogue of glutamic acid, to rat brain membranes. J. Neurochem.38, 173178. 10.1111/j.1471-4159.1982.tb10868.x

  • 112

    HouL.KlannE. (2004). Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J. Neurosci.24, 63526361. 10.1523/JNEUROSCI.0995-04.2004

  • 113

    HuganirR. L.NicollR. A. (2013). AMPARs and synaptic plasticity: the last 25 years. Neuron80, 704717. 10.1016/j.neuron.2013.10.025

  • 114

    HusiH.WardM. A.ChoudharyJ. S.BlackstockW. P.GrantS. G. (2000). Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat. Neurosci.3, 661669. 10.1038/76615

  • 115

    HussmanJ. P.ChungR. H.GriswoldA. J.JaworskiJ. M.SalyakinaD.MaD.et al. (2011). A noise-reduction GWAS analysis implicates altered regulation of neurite outgrowth and guidance in autism. Mol. Autism2:1. 10.1186/2040-2392-2-1

  • 116

    IacovelliL.BrunoV.SalvatoreL.MelchiorriD.GradiniR.CaricasoleA.et al. (2002). Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways. J. Neurochem.82, 216223. 10.1046/j.1471-4159.2002.00929.x

  • 117

    IkedaK.BekkersJ. M. (2009). Counting the number of releasable synaptic vesicles in a presynaptic terminal. Proc. Natl. Acad. Sci. U. S. A.106, 29452950. 10.1073/pnas.0811017106

  • 118

    IsaacJ. T.NicollR. A.MalenkaR. C. (1995). Evidence for silent synapses: implications for the expression of LTP. Neuron15, 427434. 10.1016/0896-6273(95)90046-2

  • 119

    IvesJ. H.FungS.TiwariP.PayneH. L.ThompsonC. L. (2004). Microtubule-associated protein light chain 2 is a stargazin-AMPA receptor complex-interacting protein in vivo. J. Biol. Chem.279, 3100231009. 10.1074/jbc.M402214200

  • 120

    JaramilloT. C.XuanZ.ReimersJ. M.EscamillaC. O.LiuS.PowellC. M. (2020). Early Restoration of Shank3 expression in Shank3 knock-out mice prevents core ASD-like behavioral phenotypes. eNeuro 7:ENEURO.0332-19.2020. 10.1523/ENEURO.0332-19.2020

  • 121

    JaskolskiF.CoussenF.MulleC. (2005). Subcellular localization and trafficking of kainate receptors. Trends Pharmacol. Sci.26, 2026. 10.1016/j.tips.2004.11.008

  • 122

    JatzkeC.WatanabeJ.WollmuthL. P. (2002). Voltage and concentration dependence of Ca(2+) permeability in recombinant glutamate receptor subtypes. J. Physiol.538(Pt 1), 2539. 10.1113/jphysiol.2001.012897

  • 123

    Jimenez-SanchezL.WongT. P.OuroA. (2024). Editorial: Regulation of AMPA receptors in brain diseases, from the genetic to the functional level, volume II. Front. Synaptic Neurosci.16:1470791. 10.3389/fnsyn.2024.1470791

  • 124

    JingamiH.NakanishiS.MorikawaK. (2003). Structure of the metabotropic glutamate receptor. Curr. Opin. Neurobiol.13, 271278. 10.1016/S0959-4388(03)00067-9

  • 125

    JohnsonJ. W.AscherP. (1987). Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature325, 529531. 10.1038/325529a0

  • 126

    JonesE. G. (1994). Santiago Ramon y Cajal and the Croonian lecture, March (1894). Trends Neurosci.17, 190192. 10.1016/0166-2236(94)90100-7

  • 127

    Julio-PieperM.FlorP. J.DinanT. G.CryanJ. F. (2011). Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues. Pharmacol. Rev.63, 3558. 10.1124/pr.110.004036

  • 128

    KabogoD.RauwG.AmritrajA.BakerG.KarS. (2010). ss-amyloid-related peptides potentiate K+-evoked glutamate release from adult rat hippocampal slices. Neurobiol. Aging31, 11641172. 10.1016/j.neurobiolaging.2008.08.009

  • 129

    KalashnikovaE.LorcaR. A.KaurI.BarisoneG. A.LiB.IshimaruT.et al. (2010). SynDIG1: an activity-regulated, AMPA- receptor-interacting transmembrane protein that regulates excitatory synapse development. Neuron65, 8093. 10.1016/j.neuron.2009.12.021

  • 130

    KamalovaA.NakagawaT. A. M. P. A. (2021). receptor structure and auxiliary subunits. J. Physiol.599, 453469. 10.1113/JP278701

  • 131

    KannerL. (1968). Autistic disturbances of affective contact. Acta Paedopsychiatr.35, 100136.

  • 132

    KawaharaY.ItoK.SunH.AizawaH.KanazawaI.KwakS. (2004). Glutamate receptors: RNA editing and death of motor neurons. Nature427:801. 10.1038/427801a

  • 133

    KeiferJ.TiwariN. K.BuseL.ZhengZ. (2017). Subunit-specific synaptic delivery of AMPA receptors by auxiliary chaperone proteins TARPgamma8 and GSG1L in classical conditioning. Neurosci. Lett.645, 5359. 10.1016/j.neulet.2017.02.041

  • 134

    KeinänenK.WisdenW.SommerB.WernerP.HerbA.VerdoornT. A.et al. (1990). A family of AMPA-selective glutamate receptors. Science249, 556560. 10.1126/science.2166337

  • 135

    KerchnerG. A.NicollR. A. (2008). Silent synapses and the emergence of a postsynaptic mechanism for LTP. Nat. Rev. Neurosci.9, 813825. 10.1038/nrn2501

  • 136

    KettenmannH.UgursuB.RansomB. R.SteinhäuserC. (2025). The concept of neuroglia - the State of the Art Circa 1900. Glia73, 890904. 10.1002/glia.24678

  • 137

    KhermeshK.D'ErchiaA. M.BarakM.AnneseA.WachtelC.LevanonE. Y.et al. (2016). Reduced levels of protein recoding by A-to-I RNA editing in Alzheimer's disease. RNA22, 290302. 10.1261/rna.054627.115

  • 138

    KhodosevichK.JacobiE.FarrowP.SchulmannA.RusuA.ZhangL.et al. (2014). Coexpressed auxiliary subunits exhibit distinct modulatory profiles on AMPA receptor function. Neuron83, 601615. 10.1016/j.neuron.2014.07.004

  • 139

    KimE.ShengM. (2004). PDZ domain proteins of synapses. Nat. Rev. Neurosci.5, 771781. 10.1038/nrn1517

  • 140

    KimI. H.WangH.SoderlingS. H.YasudaR. (2014). Loss of Cdc42 leads to defects in synaptic plasticity and remote memory recall. Elife3:e02839. 10.7554/eLife.02839

  • 141

    KirkL. M.TiS. W.BishopH. I.Orozco-LlamasM.PhamM.TrimmerJ. S.et al. (2016). Distribution of the SynDIG4/proline-rich transmembrane protein 1 in rat brain. J. Comp. Neurol.524, 22662280. 10.1002/cne.23945

  • 142

    KlaassenR. V.StroederJ.CoussenF.HafnerA. S.PetersenJ. D.RenancioC.et al. (2016). Shisa6 traps AMPA receptors at postsynaptic sites and prevents their desensitization during synaptic activity. Nat. Commun.7:10682. 10.1038/ncomms10682

  • 143

    KlecknerN. W.DingledineR. (1988). Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science241, 835837. 10.1126/science.2841759

  • 144

    KohdaK.WangY.YuzakiM. (2000). Mutation of a glutamate receptor motif reveals its role in gating and delta2 receptor channel properties. Nat. Neurosci.3, 315322. 10.1038/73877

  • 145

    KumarJ.PopescuG. K.GantzS. C. (2023). GluD receptors are functional ion channels. Biophys. J.122, 23832395. 10.1016/j.bpj.2023.05.012

  • 146

    KumarJ.SchuckP.JinR.MayerM. L. (2009). The N-terminal domain of GluR6-subtype glutamate receptor ion channels. Nat. Struct. Mol. Biol.16, 631638. 10.1038/nsmb.1613

  • 147

    KundeS. A.RademacherN.ZiegerH.ShoichetS. A. (2017). Protein kinase C regulates AMPA receptor auxiliary protein Shisa9/CKAMP44 through interactions with neuronal scaffold PICK1. FEBS Open Bio7, 12341245. 10.1002/2211-5463.12261

  • 148

    KunerT.SeeburgP. H.GuyH. R. (2003). A common architecture for K+ channels and ionotropic glutamate receptors?Trends Neurosci.26, 2732. 10.1016/S0166-2236(02)00010-3

  • 149

    KunishimaN.ShimadaY.TsujiY.SatoT.YamamotoM.KumasakaT.et al. (2000). Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature407, 971977. 10.1038/35039564

  • 150

    KuusinenA.AbeleR.MaddenD. R.KeinänenK. (1999). Oligomerization and ligand-binding properties of the ectodomain of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunit GluRD. J. Biol. Chem.274, 2893728943. 10.1074/jbc.274.41.28937

  • 151

    LaiM.HughesE. G.PengX.ZhouL.GleichmanA. J.ShuH.et al. (2009). AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann. Neurol.65, 424434. 10.1002/ana.21589

  • 152

    LanznasterD.MackJ. M.CoelhoV.GanzellaM.AlmeidaR. F.Dal-CimT.et al. (2017). Guanosine prevents anhedonic-like behavior and impairment in hippocampal glutamate transport following amyloid-beta(1-40) administration in mice. Mol. Neurobiol.54, 54825496. 10.1007/s12035-016-0082-1

  • 153

    LaubeB.KuhseJ.BetzH. (1998). Evidence for a tetrameric structure of recombinant NMDA receptors. J. Neurosci.18, 29542961. 10.1523/JNEUROSCI.18-08-02954.1998

  • 154

    LeeB.ZhangY.KimY.KimS.LeeY.HanK. (2017). Age-dependent decrease of GAD65/67 mRNAs but normal densities of GABAergic interneurons in the brain regions of Shank3-overexpressing manic mouse model. Neurosci. Lett.649, 4854. 10.1016/j.neulet.2017.04.016

  • 155

    LeuschnerW. D.HochW. (1999). Subtype-specific assembly of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits is mediated by their n-terminal domains. J. Biol. Chem.274, 1690716916. 10.1074/jbc.274.24.16907

  • 156

    LeviteM. (2014). Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. J. Neural. Transm.121, 10291075. 10.1007/s00702-014-1193-3

  • 157

    LeviteM.FleidervishI. A.SchwarzA.PelledD.FutermanA. H. (1999). Autoantibodies to the glutamate receptor kill neurons via activation of the receptor ion channel. J. Autoimmun.13, 6172. 10.1006/jaut.1999.0301

  • 158

    LiJ.ChaiA.WangL.MaY.WuZ.YuH.et al. (2015). Synaptic P-Rex1 signaling regulates hippocampal long-term depression and autism-like social behavior. Proc. Natl. Acad. Sci. U. S. A.112, E6964E6972. 10.1073/pnas.1512913112

  • 159

    LiS.HongS.ShepardsonN. E.WalshD. M.ShankarG. M.SelkoeD. (2009). Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron62, 788801. 10.1016/j.neuron.2009.05.012

  • 160

    LiX. M.LiC. C.YuS. S.ChenJ. T.SabapathyK.RuanD. Y. (2007). JNK1 contributes to metabotropic glutamate receptor-dependent long-term depression and short-term synaptic plasticity in the mice area hippocampal CA1. Eur. J. Neurosci.25, 391396. 10.1111/j.1460-9568.2006.05300.x

  • 161

    LiaoD.HesslerN. A.MalinowR. (1995). Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice. Nature375, 400404. 10.1038/375400a0

  • 162

    LinY. C.FreiJ. A.KilanderM. B.ShenW.BlattG. J. (2016). A subset of autism-associated genes regulate the structural stability of neurons. Front. Cell. Neurosci.10:263. 10.3389/fncel.2016.00263

  • 163

    LiuJ.PrindleA.HumphriesJ.Gabalda-SagarraM.AsallyM.LeeD. Y.et al. (2015). Metabolic co-dependence gives rise to collective oscillations within biofilms. Nature523, 550554. 10.1038/nature14660

  • 164

    LledoP. M.ZhangX.SüdhofT. C.MalenkaR. C.NicollR. A. (1998). Postsynaptic membrane fusion and long-term potentiation. Science279, 399403. 10.1126/science.279.5349.399

  • 165

    LomeliH.SprengelR.LaurieD. J.KöhrG.HerbA.SeeburgP. H.et al. (1993). The rat delta-1 and delta-2 subunits extend the excitatory amino acid receptor family. FEBS Lett.315, 318322. 10.1016/0014-5793(93)81186-4

  • 166

    LorgenJ. Ø.EgbenyaD. L.HammerJ.DavangerS. (2017). PICK1 facilitates lasting reduction in GluA2 concentration in the hippocampus during chronic epilepsy. Epilepsy Res.137, 2532. 10.1016/j.eplepsyres.2017.08.012

  • 167

    LüscherC.XiaH.BeattieE. C.CarrollR. C.von ZastrowM.MalenkaR. C.et al. (1999). Role of AMPA receptor cycling in synaptic transmission and plasticity. Neuron24, 649658. 10.1016/S0896-6273(00)81119-8

  • 168

    LyallK.CroenL.DanielsJ.FallinM. D.Ladd-AcostaC.LeeB. K.et al. (2017). The changing epidemiology of autism spectrum disorders. Annu. Rev. Public Health38, 81102. 10.1146/annurev-publhealth-031816-044318

  • 169

    MacGillavryH. D.SongY.RaghavachariS.BlanpiedT. A. (2013). Nanoscale scaffolding domains within the postsynaptic density concentrate synaptic AMPA receptors. Neuron78, 615622. 10.1016/j.neuron.2013.03.009

  • 170

    MakinoH.MalinowR. A. M. P. A. (2009). receptor incorporation into synapses during LTP: the role of lateral movement and exocytosis. Neuron64, 381390. 10.1016/j.neuron.2009.08.035

  • 171

    ManoI.TeichbergV. I. A. (1998). tetrameric subunit stoichiometry for a glutamate receptor-channel complex. Neuroreport9, 327331. 10.1097/00001756-199801260-00027

  • 172

    MantegazzaR.BernasconiP.BaggiF.SpreaficoR.RagonaF.AntozziC.et al. (2002). Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J. Neuroimmunol.131, 179185. 10.1016/S0165-5728(02)00261-8

  • 173

    MartinE. E.WleklinskiE.HoangH. T. M.AhmadM. (2021). Interaction and subcellular association of PRRT1/SynDIG4 with AMPA receptors. Front. Synaptic Neurosci.13:705664. 10.3389/fnsyn.2021.705664

  • 174

    MasukoT.KashiwagiK.KunoT.NguyenN. D.PahkA. J.FukuchiJ.et al. (1999). A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein. Mol. Pharmacol.55, 957969. 10.1016/S0026-895X(24)23245-4

  • 175

    MatosM.AugustoE.OliveiraC. R.AgostinhoP. (2008). Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience156, 898910. 10.1016/j.neuroscience.2008.08.022

  • 176

    MatsudaS.MiuraE.MatsudaK.KakegawaW.KohdaK.WatanabeM.et al. (2008). Accumulation of AMPA receptors in autophagosomes in neuronal axons lacking adaptor protein AP-4. Neuron57, 730745. 10.1016/j.neuron.2008.02.012

  • 177

    MattL.KirkL. M.ChenauxG.SpecaD. J.PuhgerK. R.PrideM. C.et al. (2018). SynDIG4/Prrt1 is required for excitatory synapse development and plasticity underlying cognitive function. Cell Rep.22, 22462253. 10.1016/j.celrep.2018.02.026

  • 178

    MayatE.PetraliaR. S.WangY. X.WentholdR. J. (1995). Immunoprecipitation, immunoblotting, and immunocytochemistry studies suggest that glutamate receptor delta subunits form novel postsynaptic receptor complexes. J. Neurosci.15, 25332546. 10.1523/JNEUROSCI.15-03-02533.1995

  • 179

    McKennaM. C. (2007). The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain. J. Neurosci. Res.85, 33473358. 10.1002/jnr.21444

  • 180

    MeldrumB. S. (2000). Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr. 130(4S Suppl.), 1007S−1015S. 10.1093/jn/130.4.1007S

  • 181

    MeuserD.SplittH.WagnerR.SchrempfH. (1999). Exploring the open pore of the potassium channel from Streptomyces lividans. FEBS Lett.462, 447452. 10.1016/S0014-5793(99)01579-3

  • 182

    MeyersonJ. R.ChittoriS.MerkA.RaoP.HanT. H.SerpeM.et al. (2016). Structural basis of kainate subtype glutamate receptor desensitization. Nature537, 567571. 10.1038/nature19352

  • 183

    Miguez-CabelloF.WangX. T.YanY.BrakeN.AlexanderR. P. D.PerozzoA. M.et al. (2025). GluA2-containing AMPA receptors form a continuum of Ca(2+)-permeable channels. Nature641, 537544. 10.1038/s41586-025-08736-2

  • 184

    MillerC. (2000). An overview of the potassium channel family. Genome Biol. 1:REVIEWS0004. 10.1186/gb-2000-1-4-reviews0004

  • 185

    MilliganT. A. (2021). Epilepsy: a clinical overview. Am. J. Med.134, 840847. 10.1016/j.amjmed.2021.01.038

  • 186

    MonyerH.SprengelR.SchoepferR.HerbA.HiguchiM.LomeliH.et al. (1992). Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science256, 12171221. 10.1126/science.256.5060.1217

  • 187

    MoranY.BarzilaiM. G.LiebeskindB. J.ZakonH. H. (2015). Evolution of voltage-gated ion channels at the emergence of Metazoa. J. Exp. Biol.218(Pt 4), 515525. 10.1242/jeb.110270

  • 188

    MorozL. L. (2009). On the independent origins of complex brains and neurons. Brain Behav. Evol.74, 177190. 10.1159/000258665

  • 189

    MorozL. L.RomanovaD. Y. (2021). Selective advantages of synapses in evolution. Front. Cell. Dev. Biol.9:726563. 10.3389/fcell.2021.726563

  • 190

    MosbacherJ.SchoepferR.MonyerH.BurnashevN.SeeburgP. H.RuppersbergJ. P. (1994). A molecular determinant for submillisecond desensitization in glutamate receptors. Science266, 10591062. 10.1126/science.7973663

  • 191

    MurakoshiH.WangH.YasudaR. (2011). Local, persistent activation of Rho GTPases during plasticity of single dendritic spines. Nature472, 100104. 10.1038/nature09823

  • 192

    MutoT.TsuchiyaD.MorikawaK.JingamiH. (2007). Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc. Natl. Acad. Sci. U. S. A.104, 37593764. 10.1073/pnas.0611577104

  • 193

    NairD. (2025). Available online at: https://BioRender.com/7t5y032

  • 194

    NairD.HosyE.PetersenJ. D.ConstalsA.GiannoneG.ChoquetD.et al. (2013). Super-resolution imaging reveals that AMPA receptors inside synapses are dynamically organized in nanodomains regulated by PSD95. J. Neurosci.33, 1320413224. 10.1523/JNEUROSCI.2381-12.2013

  • 195

    NakagawaT.ChengY.RammE.ShengM.WalzT. (2005). Structure and different conformational states of native AMPA receptor complexes. Nature433, 545549. 10.1038/nature03328

  • 196

    NaurP.HansenK. B.KristensenA. S.DravidS. M.PickeringD. S.OlsenL.et al. (2007). Ionotropic glutamate-like receptor delta2 binds D-serine and glycine. Proc. Natl. Acad. Sci. U. S. A.104, 1411614121. 10.1073/pnas.0703718104

  • 197

    NiesmannK.BreuerD.BrockhausJ.BornG.WolffI.ReissnerC.et al. (2011). Dendritic spine formation and synaptic function require neurobeachin. Nat. Commun.2:557. 10.1038/ncomms1565

  • 198

    NingL.ShenR.XieB.JiangY.GengX.DongW. (2024). AMPA receptors in Alzheimer's disease: pathological changes and potential therapeutic targets. J. Neuropathol. Exp. Neurol.83, 895906. 10.1093/jnen/nlae093

  • 199

    NiswenderC. M.ConnP. J. (2010). Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol.50, 295322. 10.1146/annurev.pharmtox.011008.145533

  • 200

    NoebelsJ. L.QiaoX.BronsonR. T.SpencerC.DavissonM. T. (1990). Stargazer: a new neurological mutant on chromosome 15 in the mouse with prolonged cortical seizures. Epilepsy Res.7, 129135. 10.1016/0920-1211(90)90098-G

  • 201

    NowakL.BregestovskiP.AscherP.HerbetA.ProchiantzA. (1984). Magnesium gates glutamate-activated channels in mouse central neurones. Nature307, 462465. 10.1038/307462a0

  • 202

    O'BrienR. J.KambojS.EhlersM. D.RosenK. R.FischbachG. D.HuganirR. L. (1998). Activity-dependent modulation of synaptic AMPA receptor accumulation. Neuron21, 10671078. 10.1016/S0896-6273(00)80624-8

  • 203

    O'ConnorM.ShentuY. P.WangG.HuW. T.XuZ. D.WangX. C.et al. (2020). Acetylation of AMPA receptors regulates receptor trafficking and rescues memory deficits in Alzheimer's disease. iScience23:101465. 10.1016/j.isci.2020.101465

  • 204

    OhwadaT.SagisakaS. (1987). An immediate and steep increase in ATP concentration in response to reduced turgor pressure in Escherichia coli B. Arch. Biochem. Biophys.259, 157163. 10.1016/0003-9861(87)90481-4

  • 205

    OjimaK.ShiraiwaK.SogaK.DouraT.TakatoM.KomatsuK.et al. (2021). Ligand-directed two-step labeling to quantify neuronal glutamate receptor trafficking. Nat. Commun.12:831. 10.1038/s41467-021-21082-x

  • 206

    OkunoH.AkashiK.IshiiY.Yagishita-KyoN.SuzukiK.NonakaM.et al. (2012). Inverse synaptic tagging of inactive synapses via dynamic interaction of Arc/Arg3.1 with CaMKIIbeta. Cell149, 886898. 10.1016/j.cell.2012.02.062

  • 207

    OpazoP.ChoquetD. A. (2011). three-step model for the synaptic recruitment of AMPA receptors. Mol. Cell. Neurosci.46, 18. 10.1016/j.mcn.2010.08.014

  • 208

    OpazoP.LabrecqueS.TigaretC. M.FrouinA.WisemanP. W.De KoninckP.et al. (2010). CaMKII triggers the diffusional trapping of surface AMPARs through phosphorylation of stargazin. Neuron67, 239252. 10.1016/j.neuron.2010.06.007

  • 209

    OzonoffS.Goodlin-JonesB. L.SolomonM. (2005). Evidence-based assessment of autism spectrum disorders in children and adolescents. J. Clin. Child Adolesc. Psychol.34, 523540. 10.1207/s15374424jccp3403_8

  • 210

    PageG.KhidirF. A.PainS.BarrierL.FauconneauB.GuillardO.et al. (2006). Group I metabotropic glutamate receptors activate the p70S6 kinase via both mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK 1/2) signaling pathways in rat striatal and hippocampal synaptoneurosomes. Neurochem. Int.49, 413421. 10.1016/j.neuint.2006.01.020

  • 211

    PaolettiP.Perin-DureauF.FayyazuddinA.Le GoffA.CallebautI.NeytonJ. (2000). Molecular organization of a zinc binding n-terminal modulatory domain in a NMDA receptor subunit. Neuron28, 911925. 10.1016/S0896-6273(00)00163-X

  • 212

    ParkJ. O.RubinS. A.XuY. F.Amador-NoguezD.FanJ.ShlomiT.et al. (2016). Metabolite concentrations, fluxes and free energies imply efficient enzyme usage. Nat. Chem. Biol.12, 482489. 10.1038/nchembio.2077

  • 213

    ParkP.KangH.SandersonT. M.BortolottoZ. A.GeorgiouJ.ZhuoM.et al. (2019). On the role of calcium-permeable AMPARs in long-term potentiation and synaptic tagging in the rodent hippocampus. Front. Synaptic Neurosci.11:4. 10.3389/fnsyn.2019.00004

  • 214

    PassafaroM.PiechV.ShengM. (2001). Subunit-specific temporal and spatial patterns of AMPA receptor exocytosis in hippocampal neurons. Nat. Neurosci.4, 917926. 10.1038/nn0901-917

  • 215

    PavlovP. I. (2010). Conditioned reflexes: an investigation of the physiological activity of the cerebral cortex. Ann. Neurosci.17, 136141. 10.5214/ans.0972-7531.1017309

  • 216

    PengX.HughesE. G.MoscatoE. H.ParsonsT. D.DalmauJ.Balice-GordonR. J. (2015). Cellular plasticity induced by anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann. Neurol.77, 381398. 10.1002/ana.24293

  • 217

    PennA. C.ZhangC. L.GeorgesF.RoyerL.BreillatC.HosyE.et al. (2017). Hippocampal LTP and contextual learning require surface diffusion of AMPA receptors. Nature549, 384388. 10.1038/nature23658

  • 218

    PenzesP.CahillM. E.JonesK. A.SrivastavaD. P. (2008). Convergent CaMK and RacGEF signals control dendritic structure and function. Trends Cell Biol.18, 405413. 10.1016/j.tcb.2008.07.002

  • 219

    PereaG.NavarreteM.AraqueA. (2009). Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci.32, 421431. 10.1016/j.tins.2009.05.001

  • 220

    PerozzoA. M.SchwenkJ.KamalovaA.NakagawaT.FaklerB.BowieD. (2023). GSG1L-containing AMPA receptor complexes are defined by their spatiotemporal expression, native interactome and allosteric sites. Nat. Commun.14:6799. 10.1038/s41467-023-42517-7

  • 221

    PetroffO. A. (2002). GABA and glutamate in the human brain. Neuroscientist8, 562573. 10.1177/1073858402238515

  • 222

    PinJ. P.GalvezT.PrezeauL. (2003). Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol. Ther.98, 325354. 10.1016/S0163-7258(03)00038-X

  • 223

    PizziM.SarnicoI.BoroniF.BenareseM.SteimbergN.MazzoleniG.et al. (2005). NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. Cell Death Differ.12, 761772. 10.1038/sj.cdd.4401598

  • 224

    PozoK.GodaY. (2010). Unraveling mechanisms of homeostatic synaptic plasticity. Neuron66, 337351. 10.1016/j.neuron.2010.04.028

  • 225

    PrielA.KollekerA.AyalonG.GillorM.OstenP.Stern-BachY. (2005). Stargazin reduces desensitization and slows deactivation of the AMPA-type glutamate receptors. J. Neurosci.25, 26822686. 10.1523/JNEUROSCI.4834-04.2005

  • 226

    PurcellA. E.JeonO. H.ZimmermanA. W.BlueM. E.PevsnerJ. (2001). Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology57, 16181628. 10.1212/WNL.57.9.1618

  • 227

    QuL.AkbergenovaY.HuY.SchikorskiT. (2009). Synapse-to-synapse variation in mean synaptic vesicle size and its relationship with synaptic morphology and function. J. Comp. Neurol.514, 343352. 10.1002/cne.22007

  • 228

    Ramón y CajalS. (1995). Histology of the Nervous System of Man and Vertebrates.New York, NY: Oxford University Press.

  • 229

    ReinerA.ArantR. J.IsacoffE. Y. (2012). Assembly stoichiometry of the GluK2/GluK5 kainate receptor complex. Cell Rep.1, 234240. 10.1016/j.celrep.2012.01.003

  • 230

    RogersS. W.AndrewsP. I.GahringL. C.WhisenandT.CauleyK.CrainB.et al. (1994). Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science265, 648651. 10.1126/science.8036512

  • 231

    RondardP.LiuJ.HuangS.MalhaireF.VolC.PinaultA.et al. (2006). Coupling of agonist binding to effector domain activation in metabotropic glutamate-like receptors. J. Biol. Chem.281, 2465324661. 10.1074/jbc.M602277200

  • 232

    RosenmundC.Stern-BachY.StevensC. F. (1998). The tetrameric structure of a glutamate receptor channel. Science280, 15961599. 10.1126/science.280.5369.1596

  • 233

    RossmannM.SukumaranM.PennA. C.VeprintsevD. B.BabuM. M.GregerI. H. (2011). Subunit-selective N-terminal domain associations organize the formation of AMPA receptor heteromers. EMBO J.30, 959971. 10.1038/emboj.2011.16

  • 234

    RubensteinJ. L.MerzenichM. M. (2003). Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav.2, 255267. 10.1034/j.1601-183X.2003.00037.x

  • 235

    RylaarsdamL.Guemez-GamboaA. (2019). Genetic causes and modifiers of autism spectrum disorder. Front. Cell. Neurosci.13:385. 10.3389/fncel.2019.00385

  • 236

    SagliettiL.DequidtC.KamieniarzK.RoussetM. C.ValnegriP.ThoumineO.et al. (2007). Extracellular interactions between GluR2 and N-cadherin in spine regulation. Neuron54, 461477. 10.1016/j.neuron.2007.04.012

  • 237

    SalpietroV.DixonC. L.GuoH.BelloO. D.VandrovcovaJ.EfthymiouS.et al. (2019). AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nat. Commun.10:3094. 10.1038/s41467-019-10910-w

  • 238

    SalussoliaC. L.CorralesA.TalukderI.KaziR.AkgulG.BowenM.et al. (2011). Interaction of the M4 segment with other transmembrane segments is required for surface expression of mammalian alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. J. Biol. Chem.286, 4020540218. 10.1074/jbc.M111.268839

  • 239

    SandersonJ. L.GorskiJ. A.Dell'AcquaM. L. (2016). NMDA receptor-dependent LTD requires transient synaptic incorporation of Ca(+)-permeable AMPARs mediated by AKAP150-anchored PKA and calcineurin. Neuron89, 10001015. 10.1016/j.neuron.2016.01.043

  • 240

    SandersonJ. L.ScottJ. D.Dell'AcquaM. L. (2018). Control of homeostatic synaptic plasticity by AKAP-anchored kinase and phosphatase regulation of Ca(2+)-permeable AMPA receptors. J. Neurosci. 38, 28632876. 10.1523/JNEUROSCI.2362-17.2018

  • 241

    SarloG. L.HoltonK. F. (2021). Brain concentrations of glutamate and GABA in human epilepsy: a review. Seizure91, 213227. 10.1016/j.seizure.2021.06.028

  • 242

    ScannevinR. H.HuganirR. L. (2000). Postsynaptic organization and regulation of excitatory synapses. Nat. Rev. Neurosci.1, 133141. 10.1038/35039075

  • 243

    ScheepersG. H.LycklamaA. N. J. A.PoolmanB. (2016). An updated structural classification of substrate-binding proteins. FEBS Lett.590, 43934401. 10.1002/1873-3468.12445

  • 244

    SchochS.GundelfingerE. D. (2006). Molecular organization of the presynaptic active zone. Cell Tissue Res.326, 379391. 10.1007/s00441-006-0244-y

  • 245

    SchonrockM.ThielG.LaubeB. (2019). Coupling of a viral K(+)-channel with a glutamate-binding-domain highlights the modular design of ionotropic glutamate-receptors. Commun. Biol.2:75. 10.1038/s42003-019-0320-y

  • 246

    SchorgeS.ColquhounD. (2003). Studies of NMDA receptor function and stoichiometry with truncated and tandem subunits. J. Neurosci.23, 11511158. 10.1523/JNEUROSCI.23-04-01151.2003

  • 247

    SchousboeA. (1981). Transport and metabolism of glutamate and GABA in neurons are glial cells. Int. Rev. Neurobiol.22, 145. 10.1016/S0074-7742(08)60289-5

  • 248

    SchrempfH.SchmidtO.KümmerlenR.HinnahS.MüllerD.BetzlerM.et al. (1995). A prokaryotic potassium ion channel with two predicted transmembrane segments from Streptomyces lividans. EMBO J.14, 51705178. 10.1002/j.1460-2075.1995.tb00201.x

  • 249

    SchwenkJ.HarmelN.BrechetA.ZollesG.BerkefeldH.MüllerC. S.et al. (2012). High-resolution proteomics unravel architecture and molecular diversity of native AMPA receptor complexes. Neuron74, 621633. 10.1016/j.neuron.2012.03.034

  • 250

    SchwenkJ.HarmelN.ZollesG.BildlW.KulikA.HeimrichB.et al. (2009). Functional proteomics identify cornichon proteins as auxiliary subunits of AMPA receptors. Science323, 13131319. 10.1126/science.1167852

  • 251

    SchwenkM.DutziI.EnglertS.MicolW.NajafiB.MohlerJ.et al. (2014). An intensive exercise program improves motor performances in patients with dementia: translational model of geriatric rehabilitation. J. Alzheimers. Dis.39, 487498. 10.3233/JAD-130470

  • 252

    SeeburgP. H.HartnerJ. (2003). Regulation of ion channel/neurotransmitter receptor function by RNA editing. Curr. Opin. Neurobiol.13, 279283. 10.1016/S0959-4388(03)00062-X

  • 253

    SegalM. (2005). Dendritic spines and long-term plasticity. Nat. Rev. Neurosci.6, 277284. 10.1038/nrn1649

  • 254

    SevenA. B.Barros-ÁlvarezX.de LapeyrièreM.Papasergi-ScottM. M.RobertsonM. J.ZhangC.et al. (2021). G-protein activation by a metabotropic glutamate receptor. Nature595, 450454. 10.1038/s41586-021-03680-3

  • 255

    ShafferD.HammerS. M.MonacoA. P. (1987). Infectious complications with the use of cyclosporine versus azathioprine after cadaveric kidney transplantation. Am. J. Surg.153, 381386. 10.1016/0002-9610(87)90582-4

  • 256

    ShanksN. F.SavasJ. N.MaruoT.CaisO.HiraoA.OeS.et al. (2012). Differences in AMPA and kainate receptor interactomes facilitate identification of AMPA receptor auxiliary subunit GSG1L. Cell Rep.1, 590598. 10.1016/j.celrep.2012.05.004

  • 257

    SheltonM. K.McCarthyK. D. (1999). Mature hippocampal astrocytes exhibit functional metabotropic and ionotropic glutamate receptors in situ. Glia26, 111.

  • 258

    ShengM.KimE. (2011). The postsynaptic organization of synapses. Cold Spring Harb. Perspect. Biol. 3:a005678. 10.1101/cshperspect.a005678

  • 259

    ShiS.HayashiY.EstebanJ. A.MalinowR. (2001). Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons. Cell105, 331343. 10.1016/S0092-8674(01)00321-X

  • 260

    ShiY.SuhY. H.MilsteinA. D.IsozakiK.SchmidS. M.RocheK. W.et al. (2010). Functional comparison of the effects of TARPs and cornichons on AMPA receptor trafficking and gating. Proc. Natl. Acad. Sci. U. S. A.107, 1631516319. 10.1073/pnas.1011706107

  • 261

    ShinoharaY.HiraseH. (2009). Size and receptor density of glutamatergic synapses: a viewpoint from left-right asymmetry of CA3-CA1 connections. Front. Neuroanat.3:10. 10.3389/neuro.05.010.2009

  • 262

    SiaG. M.BéïqueJ. C.RumbaughG.ChoR.WorleyP. F.HuganirR. L. (2007). Interaction of the N-terminal domain of the AMPA receptor GluR4 subunit with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. Neuron55, 87102. 10.1016/j.neuron.2007.06.020

  • 263

    SimonJ. R.ContreraJ. F.KuharM. J. (1976). Binding of [3H] kainic acid, and analogue of Lglutamate, to brain membranes. J. Neurochem.26, 141147. 10.1111/j.1471-4159.1976.tb04449.x

  • 264

    SoaresC.LeeK. F.NassrallahW.BéïqueJ. C. (2013). Differential subcellular targeting of glutamate receptor subtypes during homeostatic synaptic plasticity. J. Neurosci.33, 1354713559. 10.1523/JNEUROSCI.1873-13.2013

  • 265

    SobolevskyA. I.RosconiM. P.GouauxE. (2009). X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature462, 745756. 10.1038/nature08624

  • 266

    SomogyiP.TamásG.LujanR.BuhlE. H. (1998). Salient features of synaptic organisation in the cerebral cortex. Brain Res. Brain Res. Rev.26, 113135. 10.1016/S0165-0173(97)00061-1

  • 267

    SotoD.CoombsI. D.KellyL.FarrantM.Cull-CandyS. G. (2007). Stargazin attenuates intracellular polyamine block of calcium-permeable AMPA receptors. Nat. Neurosci.10, 12601267. 10.1038/nn1966

  • 268

    SternJ. R.EgglestonL. V.HemsR.KrebsH. A. (1949). Accumulation of glutamic acid in isolated brain tissue. Biochem. J.44, 410418. 10.1042/bj0440410

  • 269

    StevensC. F. (1986). Neurotransmission. Are there two functional classes of glutamate receptors?Nature322, 210211. 10.1038/322210a0

  • 270

    SuttonM. A.ItoH. T.CressyP.KempfC.WooJ. C.SchumanE. M. (2006). Miniature neurotransmission stabilizes synaptic function via tonic suppression of local dendritic protein synthesis. Cell125, 785799. 10.1016/j.cell.2006.03.040

  • 271

    SzatkowskiM.BarbourB.AttwellD. (1990). Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake. Nature348, 443446. 10.1038/348443a0

  • 272

    TangY. P.ShimizuE.DubeG. R.RamponC.KerchnerG. A.ZhuoM.et al. (1999). Genetic enhancement of learning and memory in mice. Nature401, 6369. 10.1038/43432

  • 273

    TapieroH.MathéG.CouvreurP.TewK. D. (2002). Glutamine I and glutamate. Biomed. Pharmacother.56, 446457. 10.1016/S0753-3322(02)00285-8

  • 274

    TecuatlC.WheelerD. W.SuttonN.AscoliG. A. (2021). Comprehensive estimates of potential synaptic connections in local circuits of the rodent hippocampal formation by axonal-dendritic overlap. J. Neurosci.41, 16651683. 10.1523/JNEUROSCI.1193-20.2020

  • 275

    TianY.TangF. L.SunX.WenL.MeiL.TangB. S.et al. (2015). VPS35-deficiency results in an impaired AMPA receptor trafficking and decreased dendritic spine maturation. Mol. Brain8:70. 10.1186/s13041-015-0156-4

  • 276

    TikhonovD. B.MagazanikL. G. (2009). Origin and molecular evolution of ionotropic glutamate receptors. Neurosci. Behav. Physiol.39, 763773. 10.1007/s11055-009-9195-6

  • 277

    TomitaS.AdesnikH.SekiguchiM.ZhangW.WadaK.HoweJ. R.et al. (2005). Stargazin modulates AMPA receptor gating and trafficking by distinct domains. Nature435, 10521058. 10.1038/nature03624

  • 278

    TomitaS.ChenL.KawasakiY.PetraliaR. S.WentholdR. J.NicollR. A.et al. (2003). Functional studies and distribution define a family of transmembrane AMPA receptor regulatory proteins. J. Cell Biol.161, 805816. 10.1083/jcb.200212116

  • 279

    TraynelisS. F.WollmuthL. P.McBainC. J.MennitiF. S.VanceK. M.OgdenK. K.et al. (2010). Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev.62, 405496. 10.1124/pr.109.002451

  • 280

    TurrigianoG. (2012). Homeostatic synaptic plasticity: local and global mechanisms for stabilizing neuronal function. Cold Spring Harb. Perspect. Biol.4:a005736. 10.1101/cshperspect.a005736

  • 281

    TurrigianoG. G.LeslieK. R.DesaiN. S.RutherfordL. C.NelsonS. B. (1998). Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature391, 892896. 10.1038/36103

  • 282

    TwomeyE. C.JiZ.WalesT. E.BodnarN. O.FicarroS. B.MartoJ. A.et al. (2019b). Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding. Science365:eaax1033. 10.1126/science.aax1033

  • 283

    TwomeyE. C.SobolevskyA. I. (2018). Structural mechanisms of gating in ionotropic glutamate receptors. Biochemistry57, 267276. 10.1021/acs.biochem.7b00891

  • 284

    TwomeyE. C.YelshanskayaM. V.GrassucciR. A.FrankJ.SobolevskyA. I. (2016). Elucidation of AMPA receptor-stargazin complexes by cryo-electron microscopy. Science353, 8386. 10.1126/science.aaf8411

  • 285

    TwomeyE. C.YelshanskayaM. V.GrassucciR. A.FrankJ.SobolevskyA. I. (2017). Channel opening and gating mechanism in AMPA-subtype glutamate receptors. Nature549, 6065. 10.1038/nature23479

  • 286

    TwomeyE. C.YelshanskayaM. V.SobolevskyA. I. (2019a). Structural and functional insights into transmembrane AMPA receptor regulatory protein complexes. J. Gen. Physiol.151, 13471356. 10.1085/jgp.201812264

  • 287

    TwymanR. E.GahringL. C.SpiessJ.RogersS. W. (1995). Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron14, 755762. 10.1016/0896-6273(95)90219-8

  • 288

    UlbrichM. H.IsacoffE. Y. (2007). Subunit counting in membrane-bound proteins. Nat. Methods4, 319321. 10.1038/nmeth1024

  • 289

    UlbrichM. H.IsacoffE. Y. (2008). Rules of engagement for NMDA receptor subunits. Proc. Natl. Acad. Sci. U. S. A.105, 1416314168. 10.1073/pnas.0802075105

  • 290

    ValentiO.ConnP. J.MarinoM. J. (2002). Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors Co-expressed in the same neuronal populations. J. Cell. Physiol.191, 125137. 10.1002/jcp.10081

  • 291

    Van Den BoschL.Van DammeP.BogaertE.RobberechtW. (2006). The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta1762, 10681082. 10.1016/j.bbadis.2006.05.002

  • 292

    VenkatesanS.SubramaniamS.RajeevP.ChopraY.JoseM.NairD. (2020). Differential scaling of synaptic molecules within functional zones of an excitatory synapse during homeostatic plasticity. eNeuro 7:ENEURO.0407-19.2020. 10.1523/ENEURO.0407-19.2020

  • 293

    VernadakisA. (1996). Glia-neuron intercommunications and synaptic plasticity. Prog. Neurobiol.49, 185214. 10.1016/S0301-0082(96)00012-3

  • 294

    VillegasJ. (1972). Axon-Schwann cell interaction in the squid nerve fibre. J. Physiol.225, 275296. 10.1113/jphysiol.1972.sp009940

  • 295

    von EngelhardtJ. (2019). AMPA receptor auxiliary proteins of the CKAMP family. Int. J. Mol. Sci.20:1460. 10.3390/ijms20061460

  • 296

    von EngelhardtJ.MackV.SprengelR.KavenstockN.LiK. W.Stern-BachY.et al. (2010). CKAMP44: a brain-specific protein attenuating short-term synaptic plasticity in the dentate gyrus. Science327, 15181522. 10.1126/science.1184178

  • 297

    WangC.GengH.LiuW.ZhangG. (2017). Prenatal, perinatal, and postnatal factors associated with autism: a meta-analysis. Medicine96:e6696. 10.1097/MD.0000000000006696

  • 298

    WangG.LiS.GilbertJ.GrittonH. J.WangZ.LiZ.et al. (2017). Crucial roles for SIRT2 and AMPA receptor acetylation in synaptic plasticity and memory. Cell Rep.20, 13351347. 10.1016/j.celrep.2017.07.030

  • 299

    WarnetX. L.Bakke KrogH.Sevillano-QuispeO. G.PoulsenH.KjaergaardM. (2021). The C-terminal domains of the NMDA receptor: how intrinsically disordered tails affect signalling, plasticity and disease. Eur. J. Neurosci.54, 67136739. 10.1111/ejn.14842

  • 300

    WatkinsJ. C.EvansR. H. (1981). Excitatory amino acid transmitters. Annu. Rev. Pharmacol. Toxicol.21, 165204. 10.1146/annurev.pa.21.040181.001121

  • 301

    WatkinsJ. C.PookP. C.SunterD. C.DaviesJ.HonoreT. (1990). Experiments with kainate and quisqualate agonists and antagonists in relation to the sub-classification of ‘non-NMDA' receptors. Adv. Exp. Med. Biol.268, 4955. 10.1007/978-1-4684-5769-8_6

  • 302

    WeberJ. P.AndrásfalvyB. K.PolitoM.MagóÁ.UjfalussyB. B.MakaraJ. K. (2016). Location-dependent synaptic plasticity rules by dendritic spine cooperativity. Nat. Commun.7:11380. 10.1038/ncomms11380

  • 303

    WhitneyK. D.McNamaraJ. O. (2000). GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J. Neurosci.20, 73077316. 10.1523/JNEUROSCI.20-19-07307.2000

  • 304

    WidagdoJ.GuntupalliS.JangS. E.AnggonoV. (2017). Regulation of AMPA Receptor Trafficking by Protein Ubiquitination. Front. Mol. Neurosci.10:347. 10.3389/fnmol.2017.00347

  • 305

    WilliamsT. L.DayN. C.InceP. G.KambojR. K.ShawP. J. (1997). Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann. Neurol.42, 200207. 10.1002/ana.410420211

  • 306

    WoZ. G.OswaldR. E. (1995). Unraveling the modular design of glutamate-gated ion channels. Trends Neurosci.18, 161168. 10.1016/0166-2236(95)93895-5

  • 307

    WrightA. L.KonenL. M.MockettB. G.MorrisG. P.SinghA.BurbanoL. E.et al. (2023). The Q/R editing site of AMPA receptor GluA2 subunit acts as an epigenetic switch regulating dendritic spines, neurodegeneration and cognitive deficits in Alzheimer's disease. Mol. Neurodegener.18:65. 10.1186/s13024-023-00632-5

  • 308

    YamazakiM.ArakiK.ShibataA.MishinaM. (1992). Molecular cloning of a cDNA encoding a novel member of the mouse glutamate receptor channel family. Biochem. Biophys. Res. Commun.183, 886892. 10.1016/0006-291X(92)90566-4

  • 309

    YamazakiM.Ohno-ShosakuT.FukayaM.KanoM.WatanabeM.SakimuraK. (2004). A novel action of stargazin as an enhancer of AMPA receptor activity. Neurosci. Res.50, 369374. 10.1016/j.neures.2004.10.002

  • 310

    YaoY.HarrisonC. B.FreddolinoP. L.SchultenK.MayerM. L. (2008). Molecular mechanism of ligand recognition by NR3 subtype glutamate receptors. EMBO J.27, 21582170. 10.1038/emboj.2008.140

  • 311

    YinS.NoetzelM. J.JohnsonK. A.ZamoranoR.Jalan-SakrikarN.GregoryK. J.et al. (2014). Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS. J. Neurosci.34, 7994. 10.1523/JNEUROSCI.1129-13.2014

  • 312

    YonezawaK.TaniH.NakajimaS.NagaiN.KoizumiT.MiyazakiT.et al. (2022). AMPA receptors in schizophrenia: a systematic review of postmortem studies on receptor subunit expression and binding. Schizophr. Res.243, 98109. 10.1016/j.schres.2022.02.033

  • 313

    YuF. H.Yarov-YarovoyV.GutmanG. A.CatterallW. A. (2005). Overview of molecular relationships in the voltage-gated ion channel superfamily. Pharmacol. Rev.57, 387395. 10.1124/pr.57.4.13

  • 314

    YuanH.ErregerK.DravidS. M.TraynelisS. F. (2005). Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3. J. Biol. Chem.280, 2970829716. 10.1074/jbc.M414215200

  • 315

    ZengM.Díaz-AlonsoJ.YeF.ChenX.XuJ.JiZ.et al. (2019). Phase separation-mediated TARP/MAGUK complex condensation and AMPA receptor synaptic transmission. Neuron104, 529543.e6. 10.1016/j.neuron.2019.08.001

  • 316

    ZhangH.JiangX.MaL.WeiW.LiZ.ChangS.et al. (2022). Role of Abeta in Alzheimer's-related synaptic dysfunction. Front. Cell Dev. Biol.10:964075. 10.3389/fcell.2022.964075

  • 317

    ZhangY.GuoO.HuoY.WangG.ManH. Y. (2018). Amyloid-beta Induces AMPA receptor ubiquitination and degradation in primary neurons and human brains of Alzheimer's disease. J. Alzheimers. Dis.62, 17891801. 10.3233/JAD-170879

  • 318

    ZhaoY.ChenS.YoshiokaC.BaconguisI.GouauxE. (2016). Architecture of fully occupied GluA2 AMPA receptor-TARP complex elucidated by cryo-EM. Nature536, 108111. 10.1038/nature18961

  • 319

    ZhouY.DanboltN. C. (2014). Glutamate as a neurotransmitter in the healthy brain. J. Neural. Transm.121, 799817. 10.1007/s00702-014-1180-8

  • 320

    ZhuJ.LeeK. Y.JewettK. A.ManH. Y.ChungH. J.TsaiN. P. (2017). Epilepsy-associated gene Nedd4-2 mediates neuronal activity and seizure susceptibility through AMPA receptors. PLoS Genet.13:e1006634. 10.1371/journal.pgen.1006634

Summary

Keywords

iGluRs, AMPA receptor (AMPAR), synaptic plasticity, TARP, neurodegenerative diseases, neurodegeneration

Citation

Francis F, Chettri D and Nair D (2025) AMPA receptors in the evolving synapse: structure, function, and disease implications. Front. Synaptic Neurosci. 17:1661342. doi: 10.3389/fnsyn.2025.1661342

Received

07 July 2025

Accepted

01 September 2025

Published

10 October 2025

Volume

17 - 2025

Edited by

Rajkumar Vutukuri, University Hospital Frankfurt, Germany

Reviewed by

Federico Javier Miguez Cabello, McGill University, Canada

Anil Annamneedi, Sai University, India

Updates

Copyright

*Correspondence: Deepak Nair

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics